This page contains a complete list of all FDA analyses conducted in the Sentinel System from the start of Mini-Sentinel in 2009 to the present.
The table below is organized at the individual analysis level (e.g., Level 1, Level 2, Query Builder, protocol-based assessment, etc.). It is designed to support searches for a specific analysis.
Alternatively, the Drug Studies table groups together related analyses that FDA conducted to address a safety concern, or set of related safety concerns. The Drug Studies page also provides important background information and describes the regulatory impact.
Note: The appearance of a drug in a Sentinel study does not mean that FDA has concluded that a causal relationship exists between the drug and the health outcome of interest. Patients and healthcare providers should refer to FDA.gov for further information about drug safety.
FDA Sentinel Analyses from ARIA and Other Sentinel Data Sources
Loading...
| Title | Medical Product | Outcomes | Date |
|---|---|---|---|
| Characterization of Dispensing Patterns of Baricitinib, Ritlecitinib, and Upadacitinib in Patients with Alopecia, Crohn's Disease, Ulcerative Colitis, and Inflammatory Bowel Disease: A Descriptive Analysis Descriptive |
baricitinib, ritlecitinib, upadacitinib
|
||
| Utilization of Selected Non-Insulin Antidiabetics in TriNetX: A Descriptive Analysis TriNetX Analysis |
non-insulin antidiabetics
|
||
| Demographic Characteristics of Incident Users of Selected Non-Insulin Antidiabetics in TriNetX: A Descriptive Analysis TriNetX Analysis |
non-insulin antidiabetics
|
||
| Clinical Characteristics of Incident Users of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) in TriNetX: A Descriptive Analysis TriNetX Analysis |
glucagon-like peptide-1 receptor agonists (GLP-1 RAs)
|
||
| Utilization of Hormonal Contraceptives Following Live-Birth or Stillbirth Delivery: A Descriptive Analysis Descriptive |
combined hormonal contraceptives (CHCs), progestin-only contraceptives (POCs)
|
||
| Risk of Severe Hyperglycemia Following Systemic Corticosteroids and Azithromycin Use in COVID-19 Patients with Type 2 Diabetes: A Sequential Surveillance Analysis Prospective Sequential Inferential |
azithromycin, corticosteroids
|
severe hyperglycemia |
|
| Corticosteroid Utilization Patterns in Hospitalized Patients With and Without a COVID-19 Diagnosis in TriNetX: A Descriptive Analysis TriNetX Analysis |
corticosteroids
|
||
| Occurrence of Absolute Neutrophil Count (ANC) Monitoring and Neutropenia Following Clozapine Use in Patients from Sentinel Data Partners that Curate ANC Laboratory Results: A Descriptive Analysis Descriptive |
clozapine
|
adherence to absolute neutrophil count (ANC) monitoring , neutropenia |
|
| Occurrence of Absolute Neutrophil Count (ANC) Monitoring, ANC Laboratory Results, and Neutropenia Following Clozapine Use: A Descriptive Analysis Descriptive |
clozapine
|
adherence to absolute neutrophil count (ANC) monitoring , neutropenia |
|
| Characterization of Users of Inclisiran in TriNetX: A Descriptive Analysis TriNetX Analysis |
inclisiran
|
||
| Utilization of Guselkumab, Risankizumab, Tildrakizumab, and Brodalumab: Third Descriptive Analysis Descriptive |
brodalumab, guselkumab, risankizumab, tildrakizumab
|
||
| Clozapine Use: First Descriptive Analysis Descriptive |
clozapine
|
||
| Clozapine Use: Second Descriptive Analysis Descriptive |
clozapine
|
||
| Adherence to Absolute Neutrophil Count (ANC) Monitoring Recommendations Following Clozapine Use: First Descriptive Analysis Descriptive |
clozapine
|
adherence to absolute neutrophil count (ANC) monitoring |
|
| Adherence to Absolute Neutrophil Count (ANC) Monitoring Recommendations Following Clozapine Use: Second Descriptive Analysis Descriptive |
clozapine
|
adherence to absolute neutrophil count (ANC) monitoring |
|
| Adherence to Absolute Neutrophil Count (ANC) Monitoring Recommendations Following Clozapine Use: Third Descriptive Analysis Descriptive |
clozapine
|
adherence to absolute neutrophil count (ANC) monitoring |
|
| Rates of Nervous System Disorders Following Bortezomib Use in Patients: A Descriptive Analysis Descriptive |
bortezomib
|
utilization |
|
| Cancer Rates Among Individuals with Loop Diuretics Exposure: A Descriptive Analysis Descriptive |
bumetanide, loop diuretics
|
||
| Utilization of Valsartan: A Descriptive Analysis Descriptive |
valsartan
|
||
| Utilization of Risankizumab and Comparator Products: A Descriptive Analysis Descriptive |
brodalumab, guselkumab, ixekizumab, risankizumab, secukinumab, tildrakizumab, ustekinumab
|
||
| Utilization of Proton Pump Inhibitors (PPIs), Single-Agent H2 Receptor Antagonists (H2RAs), and Famotidine in Patients with Gastroesophageal Reflux Disease (GERD): A Descriptive Analysis Descriptive |
famotidine, proton pump inhibitors, single-agent H2 receptor antagonists
|
||
| Characterization of Users of Atogepant in TriNetX: A Descriptive Analysis TriNetX Analysis |
atogepant
|
||
| Trends in Single-Dose Doxycycline for Lyme Disease Prophylaxis in the United States: A Descriptive Analysis Descriptive |
doxycycline
|
||
| Trends in Single-Dose Doxycycline for Lyme Disease Prophylaxis in the United States: An Updated Descriptive Analysis Descriptive |
doxycycline
|
||
| Trends in Healthcare Encounters with Evidence of Disorders Related to the Use, Abuse, or Dependence of Cannabis, Cocaine, or Alcohol: A Descriptive Analysis Descriptive |
alcohol, cannabis, cocaine
|
substance use disorder |
|
| Trends in Healthcare Encounters with Evidence of Poisoning by Cannabis, Cocaine, Alcohol, Heroin, or Benzodiazepines: A Descriptive Analysis Descriptive |
alcohol, benzodiazepines, cannabis, cocaine, heroin
|
poisoning |
|
| Characteristics of Patients with Healthcare Encounters Involving Disorders or Poisoning Related to Cannabis, Cocaine, Alcohol, Heroin, or Benzodiazepines: A Descriptive Analysis Descriptive |
alcohol, benzodiazepines, cannabis, cocaine, heroin
|
poisoning , substance use disorder |
|
| Characteristics of Patients with Healthcare Encounters Involving Disorders or Poisoning Related to Cannabis: A Descriptive Analysis Descriptive |
cannabis
|
poisoning , substance use disorder |
|
| Trends in Healthcare Encounters Involving Disorders or Poisoning Related to Cannabis, Stratified by the Legality Status of Cannabis by State and Territory: A Descriptive Analysis Descriptive |
cannabis
|
poisoning , substance use disorder |
|
| Outcome Monitoring Following Guselkumab Use: A Signal Identification and Self-Controlled Risk Interval Analysis Signal Identification |
guselkumab
|
||
| Utilization of Methotrexate: A Descriptive Analysis Descriptive |
methotrexate
|
||
| Prevalence of Selected Conditions Among Individuals with Childbearing Potential: A Second Descriptive Analysis Descriptive |
|||
| Counts and Characteristics of Local Anesthetic Toxicity Summary Table |
local anesthetics
|
anesthetic toxicity |
|
| Utilization of Products with Labeling Changes Related to Pregnancy Among Mothers with Live-Birth Deliveries: A Descriptive Analysis Descriptive |
products with labeling changes related to pregnancy
|
||
| Outcome Monitoring Following Risankizumab Use: A Signal Identification Analysis Signal Identification |
risankizumab
|
signal identification |
|
| Outcome Monitoring Following Risankizumab Use: A Supplemental Signal Identification Analysis Signal Identification |
risankizumab
|
signal identification |
|
| Outcome Monitoring Following Guselkumab Use: A Signal Identification Analysis Signal Identification |
guselkumab, risankizumab
|
||
| Counts and Characteristics of Individuals with Prurigo Nodularis and Other Dermatologic Conditions: A Descriptive Analysis Descriptive |
prurigo nodularis |
||
| Hydrochlorothiazide Use Following Labeling Update to Include the Risk of Non-Melanoma Skin Cancer: An Updated Interrupted Time Series Analysis Retrospective Inferential |
hydrochlorothiazide
|
||
| Trends in Healthcare Utilization During the COVID-19 Pandemic: A Propensity Score Matched and Stratified Analysis in the Sentinel Distributed Database Retrospective Inferential |
ACE inhibitors, beta blockers
|
angioedema |
|
| Trends in Healthcare Utilization During the COVID-19 Pandemic: A Propensity Score Matched and Stratified Analysis in Merative™ MarketScan® Research Databases Retrospective Inferential |
ACE inhibitors, beta blockers
|
angioedema |
|
| Characteristics and Drug Utilization in Dabigatran, Rivaroxaban, and Apixaban Initiators Aged 64 or Younger: A Descriptive Analysis Descriptive |
apixaban, dabigatran, rivaroxaban
|
||
| Thromboembolic Stroke, Intracranial Hemorrhage, Gastrointestinal Bleeding, and Major Extracranial Bleeding Following Apixaban, Dabigatran, and Rivaroxaban Use in Patients Aged 64 Years and Younger with Atrial Fibrillation: An Inverse Probability of Treatment Weighting Analysis Retrospective Inferential |
apixaban, dabigatran, rivaroxaban
|
gastrointestinal bleeding , intracranial hemorrhage , major extracranial hemorrhage , thromboembolic stroke |
|
| Characterization of Infants in the Mother-Infant Linkage Table in the Sentinel Distributed Database: An Updated Descriptive Analysis Descriptive |
|||
| Characteristics and Drug Utilization in Pregnant Patients With COVID-19: A Propensity Score Matched Analysis Retrospective Inferential |
|||
| Risk of Adverse Maternal Health Outcomes Among Pregnant Patients With and Without COVID-19: A Propensity Score Matched Analysis Retrospective Inferential |
adverse maternal outcomes |
||
| Risk of Adverse Neonatal Health Outcomes Among Pregnant Patients With and Without COVID-19: A Propensity Score Matched Analysis Retrospective Inferential |
adverse neonatal outcomes |
||
| Utilization of Dupilumab: A Descriptive Analysis Descriptive |
dupilumab
|
||
| Duration of Follow Up for New Molecular Entities Approved in 2017: Third Descriptive Analysis Descriptive |
new molecular entities (NMEs)
|
||
| Duration of Follow Up for New Molecular Entities Approved in 2018: Second Descriptive Analysis Descriptive |
new molecular entities (NMEs)
|
||
| Duration of Follow Up for New Molecular Entities Approved in 2019: Second Descriptive Analysis Descriptive |
new molecular entities (NMEs)
|
||
| Duration of Follow Up for New Molecular Entities Approved in 2020: First Descriptive Analysis Descriptive |
new molecular entities (NMEs)
|
||
| Duration of Follow Up for New Molecular Entities Approved in 2021: First Descriptive Analysis Descriptive |
new molecular entities (NMEs)
|
||
| Prevalence of Selected Conditions Among Individuals with Childbearing Potential: A Descriptive Analysis Descriptive |
|||
| Intentional Self-Harm Following Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) Use in Patients with Obesity: A Descriptive Analysis Descriptive |
glucagon-like peptide-1 (GLP-1) receptor agonists
|
intentional self-harm |
|
| Intentional Self-Harm Following Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) Use in Patients with Diabetes: An Inverse Probability of Treatment Weighting Analysis Retrospective Inferential |
glucagon-like peptide-1 (GLP-1) receptor agonists
|
intentional self-harm |
|
| Utilization of Methotrexate: A Descriptive Analysis in TriNetX TriNetX Analysis |
methotrexate
|
||
| Utilization of Ibrexafungerp in Pregnant Patients: An Updated Descriptive Analysis Descriptive |
ibrexafungerp
|
||
| Counts and Characteristics of Dipeptidyl Peptidase-4 (DPP-4) Inhibitor or Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitor Users with Type 2 Diabetes: A Descriptive Analysis Descriptive |
dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT-2) inhibitors
|
||
| Serious Infection Following Ustekinumab Use in Patients with Crohn’s Disease: An Inverse Probability of Treatment Weighting Analysis Retrospective Inferential |
ustekinumab
|
serious infection |
|
| Characterization of Pediatric Demographics and Enrollment in the Sentinel Distributed Database: An Updated Descriptive Analysis Descriptive |
|||
| Characterization of Users of New Molecular Entities Approved in 2021 in TriNetX: An Updated Descriptive Analysis TriNetX Analysis |
new molecular entities (NMEs)
|
||
| Utilization of Beta Blockers in the Pediatric Population: A Follow Up Updated Descriptive Analysis Descriptive |
beta blockers
|
||
| Concomitant Use of Medications with Drug-Drug Interactions with Nirmatrelvir and Ritonavir Among Patients Treated with Nirmatrelvir and Ritonavir or Patients with COVID-19: A Descriptive Analysis Descriptive |
nirmatrelvir and ritonavir
|
||
| Utilization of Ibrexafungerp in Pregnant Patients: An Updated Descriptive Analysis in TriNetX TriNetX Analysis |
ibrexafungerp
|
||
| Duration of Follow Up for New Molecular Entities Approved in 2007: A Descriptive Analysis Summary Table |
new molecular entities (NMEs)
|
||
| Interstitial Lung Disease (ILD) in Patients with Inflammatory Bowel Disease (IBD) and Following Vedolizumab or Natalizumab Initiation: A Descriptive Analysis Descriptive |
natalizumab, vedolizumab
|
interstitial lung disease |
|
| Interstitial Lung Disease (ILD) Rates in Patients with Inflammatory Bowel Disease (IBD) and Following IBD Advanced Therapy: A Descriptive Analysis Descriptive |
adalimumab, certolizumab, etrasimod, golimumab, infliximab, mirikizumab, ozanimod, risankizumab, tofacitinib, upadacitinib, ustekinumab
|
interstitial lung disease |
|
| Hydrochlorothiazide Use Following Labeling Update to Include the Risk of Non-Melanoma Skin Cancer: An Interrupted Time Series Analysis Retrospective Inferential |
hydrochlorothiazide
|
||
| Validation of Hospitalized COVID-19 Diagnosis Detected from Claims-Based Algorithms: A Descriptive Analysis Site-Specific Query |
COVID-19 |
||
| Utilization of Products Over Time for the Development of the Pregnancy Safety Study Framework Among Mothers with Live-Birth Deliveries: A Descriptive Analysis Descriptive |
products for the development of the pregnancy safety study framework
|
use in pregnancy |
|
| Utilization of Loop Diuretics: A Descriptive Analysis Descriptive |
bumetanide, loop diuretics
|
||
| Characterization of Users of New Molecular Entities Approved in 2021 in TriNetX: A Descriptive Analysis TriNetX Analysis |
new molecular entities (NMEs)
|
||
| Count and Duration of Follow-up of New-Onset Cancer: A Descriptive Analysis Descriptive |
|||
| Intentional Self-Harm Following Montelukast Use in Patients with Asthma: An Updated Analysis Using ICD-10-CM Coding Retrospective Inferential |
inhaled corticosteroids, montelukast
|
intentional self-harm |
|
| Arterial and Venous Thrombotic Events in Patients with COVID-19 in Inpatient and Ambulatory Settings: A Descriptive Analysis Descriptive |
arterial thromboembolism , venous thromboembolism |
||
| Racial and Ethnic Differences in the Clinical Characteristics of Patients with Various Stages of COVID-19: A Descriptive Analysis PCORnet Descriptive Analysis |
|||
| Utilization and Coding Patterns of Long-Acting Injectable Antipsychotics (LAIA): A Descriptive Analysis Descriptive |
long-acting injectable antipsychotics
|
||
| Characterization of Gimoti (Metoclopramide Nasal Spray) Dispensing Patterns: A Descriptive Analysis Descriptive |
Gimoti (metoclopramide nasal spray)
|
||
| Characterization of Gimoti (Metoclopramide Nasal Spray) Dispensing Patterns: An Updated Descriptive Analysis Descriptive |
Gimoti (metoclopramide nasal spray)
|
||
| Ustekinumab and Comparator Treatment Utilization and Pneumonia Outcomes in Patients with Crohn's Disease or Ulcerative Colitis: An Updated Descriptive Analysis Descriptive |
adalimumab, infliximab, ustekinumab, vedolizumab
|
pneumonia (Chron's disease) , pneumonia (ulcerative colitis) |
|
| Capture of Long COVID in TriNetX: A Descriptive Analysis TriNetX Analysis |
post-acute COVID-19 syndrome |
||
| Occurrence of Stroke, Intracranial Hemorrhage, and Bleeding Outcomes Following Direct Oral Anticoagulant Use in Patients Aged 64 or Younger with Atrial Fibrillation: A Descriptive Analysis Descriptive |
apixaban, dabigatran, edoxaban, rivaroxaban
|
gastrointestinal bleeding , intracranial hemorrhage , major extracranial bleeding , thromboembolic stroke |
|
| Counts and Characteristics of Long-Acting Injectable Antipsychotic (LAIA) Users: A Descriptive Analysis Descriptive |
long-acting injectable antipsychotics
|
||
| Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor Use in Patients with Diabetes Mellitus: A Descriptive Analysis Descriptive |
SGLT2 inhibitors
|
||
| Outcome Monitoring Following Dupilumab Use: A Signal Identification Analysis Signal Identification |
dupilumab
|
||
| Mixed Amphetamine Salts Immediate-Release Tablet Use: A Descriptive Analysis Descriptive |
mixed amphetamine salts immediate-release tablets
|
||
| Outcome Monitoring Following Baloxavir Use: A Signal Identification Analysis Signal Identification |
baloxavir
|
||
| Hydrochlorothiazide Use Following Labeling Update to Include the Risk of Non-Melanoma Skin Cancer: A Descriptive Analysis Descriptive |
hydrochlorothiazide
|
utilization |
|
| Medication Use Among Pregnant Individuals With COVID-19: A Descriptive Analysis Descriptive |
|||
| Utilization of Drug-Device or Biologic-Device Combinations: A Descriptive Analysis Descriptive |
|||
| Lipiodol (Ethiodized Oil) and Other Non-Oil Based Iodine Imaging Agent Utilization Patterns: A Descriptive Analysis Descriptive |
Lipiodol (ethiodized oil)
|
||
| Utilization of Guselkumab, Risankizumab, Tildrakizumab, and Brodalumab: Second Descriptive Analysis Descriptive |
brodalumab, guselkumab, risankizumab, tildrakizumab
|
||
| Counts and Characteristics of Pegylated Liposomal Doxorubicin and Non-Liposomal Doxorubicin Users: A Descriptive Analysis Descriptive |
non-liposomal doxorubicin, pegylated liposomal doxorubicin
|
||
| Characterization of Cannabis-Derived Product Users in the National Patient-Centered Clinical Research Network (PCORnet): A Descriptive Analysis PCORnet Descriptive Analysis |
cannabis-derived products
|
||
| Risk of Non-Cardiac Congenital Malformations Following Armodafinil or Modafinil Use: A Propensity Score Matched Analysis Retrospective Inferential |
armodafinil, modafinil
|
non-cardiac congenital malformations |
|
| Utilization of Drugs with Approved Risk Evaluation and Mitigation Strategies (REMS) That Employ Elements to Assure Safe Use (ETASU): A Descriptive Analysis Descriptive |
alosetron, alvimopan, clozapine, collagenase clostridium histolyticum, denosumab, eculizumab, idelalisib, isotretinoin, lenalidomide, mifepristone, mycophenolate, natalizumab, olanzapine extended release, panobinostat, phentermine/topiramate, pomalidomide, romiplostim, teduglutide, testosterone undecanoate, vigabatrin
|
||
| Racial and Ethnic Differences in COVID-19 Treatment and Mortality in TriNetX: A Descriptive Analysis TriNetX Analysis |
|||
| Utilization, Dispensing, and Coding Patterns of Biologics and Biosimilars in the Sentinel Distributed Database: A Descriptive Analysis Descriptive |
Neulasta (pegfilgrastim), Neupogen (filgrastim), Remicade (infliximab)
|
biosimilar use |
|
| COVID-19 Hospitalization and Severe COVID-19 Infection Following Proton Pump Inhibitor (PPI) Use in Patients with Gastroesophageal Reflux Disease (GERD): An Inverse Probability of Treatment Weighting Analysis Retrospective Inferential |
proton pump inhibitors
|
COVID-19 hospitalization , Severe COVID-19 |
|
| Characterization of Use of Biologics and Biosimilars in the Sentinel Distributed Database: A Descriptive Analysis Descriptive |
Neupogen (filgrastim), Remicade (infliximab)
|
biosimilar use |
|
| Utilization of Ibrexafungerp in Pregnant Patients: A Descriptive Analysis Descriptive |
ibrexafungerp
|
||
| Utilization of Products for the Development of the Pregnancy Safety Study Framework Among Mothers Linked to Live-Birth Deliveries in the Mother-Infant Linkage Table: A Descriptive Analysis Descriptive |
products for the development of the pregnancy safety study framework
|
use in pregnancy |
|
| Utilization of Products for the Development of the Pregnancy Safety Study Framework Among Mothers with Live-Birth Deliveries: A Descriptive Analysis Descriptive |
products for the development of the pregnancy safety study framework
|
use in pregnancy |
|
| Baloxavir and Oseltamivir Utilization: A Descriptive Analysis Descriptive |
baloxavir, oseltamivir
|
||
| Bevacizumab and Other Cancer Medication Use in Pregnant Patients: A Descriptive Analysis Summary Table |
bevacizumab, pegaptanib, ranibizumab, verteporfin
|
||
| Incident Utilization of Allopurinol, Hydralazine, and Propylthiouracil: A Descriptive Analysis Summary Table |
allopurinol, hydralazine, propylthiouracil
|
||
| Incident Utilization Patterns of Obesity Drugs: A Descriptive Analysis Summary Table |
obesity drugs
|
||
| Utilization and Switching Patterns of Mixed Amphetamine Salt (MAS) Products in Patients with Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy: A Descriptive Analysis Descriptive |
mixed amphetamine salts
|
switching patterns |
|
| Utilization of Beta Blockers in the Pediatric Population: An Updated Descriptive Analysis Descriptive |
beta blockers
|
||
| Utilization of Beta Blockers in the Pediatric Population: A Descriptive Analysis Descriptive |
beta blockers
|
||
| Characterization of Cannabis-Derived Product Users in TriNetX: Five Descriptive Analyses TriNetX Analysis |
cannabis-derived products
|
||
| Baricitinib or Tocilizumab Use in Hospitalized Patients with a COVID-19 Diagnosis: A Descriptive Analysis PCORnet Descriptive Analysis |
baricitinib, tocilizumab
|
emergency use authorization (EUA) utilization |
|
| Prevalence and Characterization of Pharmacogenetic Testing Healthcare Common Procedure Coding System (HCPCS) Procedure Codes in the Mini-Sentinel Distributed Database (MSDD): A Descriptive Analysis Summary Table |
pharmacogenetic testing
|
||
| Dupixent (Dupilumab) Utilization Patterns: A Descriptive Analysis Descriptive |
dupilumab dupixent
|
||
| Alosetron and Eluxadoline Use: A Descriptive Analysis Descriptive |
alosetron, eluxadoline
|
||
| Renal Cell Carcinoma Following Canagliflozin Use in Patients with Type 2 Diabetes: A Descriptive Analysis Descriptive |
canagliflozin
|
renal cell carcinoma |
|
| Outcome Monitoring Following Erenumab Use: A Signal Identification Analysis Signal Identification |
erenumab
|
||
| Mortality Following Long-Acting Injectable Antipsychotics Use in Patients with Dementia: An Inverse Probability of Treatment Weighting Analysis Retrospective Inferential |
long-acting injectable antipsychotics
|
mortality |
|
| Biologics Use in Adults with Ulcerative Colitis: A Descriptive Analysis Descriptive |
adalimumab, golimumab, infliximab, vedolizumab
|
||
| Ischemic Colitis Following Alosetron Use: A Descriptive Analysis Descriptive |
alosetron
|
ischemic colitis |
|
| Utilization and Switching Patterns of Inhaled Corticosteroid/Long Acting Beta Agonist and Advair Diskus in Patients with Asthma or Chronic Obstructive Pulmonary Disease: A Descriptive Analysis Descriptive |
Advair Diskus, fluticasone salmeterol
|
brand to generic switching |
|
| Brand to Generic Switching Patterns Among Advair Diskus Users with Asthma or Chronic Obstructive Pulmonary Disease (COPD): A Descriptive Analysis Descriptive |
Advair Diskus, fluticasone salmeterol
|
brand to generic switching |
|
| Insulin Coding Practices: A Descriptive Analysis Descriptive |
insulin
|
||
| Angioedema Following Sacubitril/Valsartan Use in Patients with Heart Failure: An Updated Propensity Score Matched Analysis Retrospective Inferential |
sacubitril/valsartan
|
angioedema |
|
| Angioedema Following Sacubitril/Valsartan Use in Patients with Heart Failure: A Propensity Score Analysis Retrospective Inferential |
sacubitril/valsartan
|
angioedema |
|
| Use of Gonadotropin-Releasing Hormone (GnRH) Agonists in Patients with Gender Dysphoria: A Descriptive Analysis Descriptive |
gonadotropin-releasing hormone agonists
|
duration of use |
|
| Utilization of Select Products for Migraine Treatment and Prevention: A Descriptive Analysis Descriptive |
eptinezumab, erenumab-aooe, fremanezumab, galcanezumab, rimegepant, ubrogepant
|
||
| Utilization of Select Biological Products: A Descriptive Analysis Descriptive |
Avastin (bevacizumab), Epogen (epoetin alfa), Inflectra (infliximab-dyyb), Mvasi (bevacizumab-awwb), Neupogen (filgrastim), Remicade (infliximab), Renflexis (infliximab-abda), Retacrit (epoetin alfa-epbx), Zarxio (filgrastim-sndz), Zirabev (bevacizumab-bvzr)
|
||
| Outcome Monitoring Following Zarxio Use: An Updated Signal Identification Analysis Signal Identification |
Zarxio (filgrastim-sndz)
|
||
| Congenital Malformations Observed in the Mother’s or Linked Infant’s Records Following Fingolimod Use During Pregnancy: A Descriptive Analysis Descriptive |
fingolimod
|
all congenital malformations , congenital cardiac malformations (primary) , congenital urinary malformations (primary) |
|
| Congenital Malformations Observed in the Mother’s Records Following Fingolimod Use During Pregnancy: A Descriptive Analysis Descriptive |
fingolimod
|
all congenital malformations , congenital cardiac malformations (primary) , congenital urinary malformations (primary) |
|
| Cardiovascular Outcomes Following Percutaneous Transluminal Septal Myocardial Ablation (PTSMA) Procedures: A Descriptive Analysis Descriptive |
dehydrated alcohol
|
atrioventricular block , heart failure , permanent pacemaker placement , septal myectomy , ventricular arrhythmia |
|
| Cardiovascular Outcomes Following Percutaneous Transluminal Septal Myocardial Ablation (PTSMA) Procedures: An Updated Descriptive Analysis Descriptive |
dehydrated alcohol
|
atrioventricular block , heart failure , myocardial infarction , permanent pacemaker placement , septal myectomy , ventricular arrhythmia |
|
| Characterization of Patients and Encounters in the TriNetX Live USA Network: A Descriptive Analysis TriNetX Analysis |
|||
| Identifying Potential Risk Factors for Respiratory Failure: A Covariate Stratified Analysis Retrospective Inferential |
acute respiratory failure |
||
| Exploring Claims-Based Definitions of, and Characterizing Patients with, Respiratory Failure: A Descriptive Analysis Descriptive |
acute respiratory failure |
||
| Utilization of Ixekizumab in Pregnant Patients: A Descriptive Analysis Descriptive |
ixekizumab
|
||
| Outcome Monitoring Following Ozempic Use in Patients with Type 2 Diabetes: A Signal Identification Analysis Signal Identification |
Ozempic (semaglutide)
|
||
| Outcome Monitoring Following Zarxio Use: A Signal Identification Analysis Signal Identification |
Zarxio (filgrastim-sndz)
|
||
| Utilization of Ibrexafungerp in Pregnant Patients: A Descriptive Analysis in TriNetX TriNetX Analysis |
ibrexafungerp
|
||
| Fractures Following Leuprolide Acetate Use: A Multiple Factor Matched Analysis Retrospective Inferential |
leuprolide acetate
|
any fracture , hip replacement , major fracture (primary) , temporomandibular joint replacement |
|
| Fractures Following Leuprolide Acetate Use: A Multiple Factor Matched Analysis (A Follow-up to a Previous Analysis) Retrospective Inferential |
leuprolide acetate
|
any fracture , hip replacement , major fracture (primary) , temporomandibular joint replacement |
|
| Comparative Effectiveness of Azithromycin Relative to Roflumilast in Individuals With Uncontrolled Chronic Obstructive Pulmonary Disease Despite Triple Inhaled Therapy | azithromycin, roflumilast
|
hospitalization and death |
|
| Use of Monoclonal Antibodies (mAbs) Under an Emergency Use Authorization (EUA) in Patients with COVID-19 Diagnosis: An Updated Descriptive Analysis Descriptive |
bamlanivimab, bamlanivimab etesevimab, casirivimab imdevimab
|
utilization |
|
| Differences in COVID-19 Testing, Positivity, Hospitalization, and Mortality by Race and Ethnicity in the Sentinel Distributed Database: A Descriptive Analysis Descriptive |
|||
| Utilization of Obesity Drugs: A Descriptive Analysis Descriptive |
obesity drugs
|
||
| Hospitalization and Anaphylaxis Following Monoclonal Antibodies (mAb) Use in Patients with COVID-19: A Descriptive Analysis Descriptive |
bamlanivimab, bamlanivimab etesevimab, casirivimab imdevimab, sotrovimab
|
anaphylaxis , hospitalization |
|
| Utilization of Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitor Drugs: A Descriptive Analysis Summary Table |
obesity drugs, sodium-glucose co-transporter-2 (SGLT-2) inhibitor
|
||
| Characterization of Infants in the Mother-Infant Linkage Table in the Sentinel Distributed Database: A Descriptive Analysis Descriptive |
|||
| Seizures Following Gadolinium-Based Contrast Agents Exposure: A Self-Controlled Risk Interval Analysis Retrospective Inferential |
gadolinium-based contrast agents (GBCA)
|
seizure |
|
| Tacrolimus Use in Patients Following Liver or Kidney Transplants: A Descriptive Analysis Descriptive |
tacrolimus
|
||
| Use of Monoclonal Antibodies (mAbs) Under an Emergency Use Authorization (EUA) in Patients with COVID-19 Diagnosis: A Descriptive Analysis Descriptive |
bamlanivimab, bamlanivimab etesevimab, casirivimab imdevimab
|
utilization |
|
| Count and Duration of Follow-up of New-Onset Cancer: An Updated Descriptive Analysis Descriptive |
|||
| Characterizing Pregnant Women With and Without Evidence of Heart Failure and Non-Pregnant Women With Heart Failure: A Propensity Score Matched Analysis Retrospective Inferential |
|||
| Bamlanivimab, Bamlanivimab and Etesevimab, and Casirivimab-Imdevimab Use in Patients with COVID-19: A Descriptive Analysis Descriptive |
bamlanivimab, bamlanivimab etesevimab, casirivimab imdevimab
|
utilization |
|
| Outpatient Corticosteroid Use in Patients With COVID-19: An Updated Descriptive Analysis Descriptive |
corticosteroids
|
||
| Outpatient Corticosteroid Use in Patients With COVID-19: A Descriptive Analysis Descriptive |
corticosteroids
|
||
| Serious Infection Following Ustekinumab Use in Patients with Crohn’s Disease or Ulcerative Colitis: A Descriptive Analysis Descriptive |
adalimumab, infliximab, ustekinumab, vedolizumab
|
serious infection (Crohn’s disease) , serious infection (ulcerative colitis) |
|
| Characterization of Pediatric Demographics and Enrollment in the Sentinel Distributed Database: A Descriptive Analysis Descriptive |
|||
| Death Data Exploration: A Descriptive Analysis Custom Code |
|||
| Thromboembolic Stroke, Major Extracranial Bleeding, Gastrointestinal Bleeding, and Intracranial Hemorrhage following Direct Oral Anticoagulant Use in Patients Aged 65 or Older: An Inverse Probability of Treatment Weighting (IPTW) Analysis Retrospective Inferential |
apixaban, dabigatran, rivaroxaban
|
gastrointestinal bleeding , intracranial hemorrhage , major extracranial bleeding , thromboembolic stroke |
|
| Incidence and Prevalence of Confounding Variables Over Time in the Sentinel Distributed Database (SDD): A Descriptive Analysis Descriptive |
|||
| Duration of Follow Up for New Molecular Entities Approved in 2018: First Descriptive Analysis Descriptive |
new molecular entities (NMEs)
|
||
| Counts and Characteristics of Individuals 25 Years Old or Younger With Drug-Device or Biologic-Device Combination Use: A Descriptive Analysis Descriptive |
drug device combinations
|
||
| Utilization of Brodalumab: A Descriptive Analysis Descriptive |
brodalumab
|
||
| Estimated Prevalence of Glomerular Diseases: An Updated Descriptive Analysis Descriptive |
glomerular diseases |
||
| Estimated Prevalence of Glomerular Diseases: A Descriptive Analysis Descriptive |
glomerular diseases |
||
| Hydroxyurea Use Among Patients with Sickle Cell Disease (SCD): A Descriptive Analysis Descriptive |
hydroxyurea
|
||
| Epidiolex (Prescription Cannabidiol) Utilization Patterns: A Descriptive Analysis Descriptive |
Epidiolex (prescription cannabidiol)
|
||
| Valganciclovir Use in Children with Congenital Cytomegalovirus Disease (cCMV) or Cytomegalovirus (CMV) Infection: A Descriptive Analysis Descriptive |
valganciclovir
|
congenital cmv |
|
| Incident and Prevalent Use of Loop Diuretics: A Descriptive Analysis Descriptive |
loop diuretics
|
||
| Human Epidermal Growth Factor Receptor 2 (HER2) Antagonist Use in Patients with Live Birth Deliveries: A Descriptive Analysis Descriptive |
HER2 antagonists
|
||
| Drug Utilization Over Time for Six Drug Classes Descriptive |
ace inhibitors, beta blockers, granulocyte colony-stimulating factor (GC-SF), intravenous (IV) iron, statins, tumor necrosis factor (TNF) alpha inhibitor
|
||
| Mometasone Furoate Sinus Implant Use in Patients with Nasal Polyps: A Descriptive Analysis Descriptive |
mometasone sinus implant
|
||
| Incidence and Prevalence of N-Nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA) Contaminated Valsartan Use: A Descriptive Analysis Descriptive |
valsartan
|
||
| Bleeding Events and Venous Thromboembolism (VTE) following Enoxaparin Use: A Descriptive Analysis Descriptive |
enoxaparin
|
hospitalized bleeding , major bleeding , venous thromboembolism (VTE) |
|
| Tofacitinib, Disease-Modifying Anti-Rheumatic Drugs (DMARDs) and Tumor Necrosis Factor Inhibitors (TNFi) Use: A Descriptive Analysis Descriptive |
disease-modifying anti-rheumatic drugs (DMARDs), tofacitinib, tumor necrosis factor inhibitors (TNFi)
|
||
| N‐nitrosodimethylamine (NDMA)‐Contaminated and Non‐NDMA‐Contaminated Valsartan Use: A Descriptive Analysis Descriptive |
valsartan
|
||
| Duration of Follow Up for New Molecular Entities Approved in 2019: First Descriptive Analysis Descriptive |
new molecular entities (NMEs)
|
||
| Duration of Follow Up for New Molecular Entities Approved in 2017: Second Descriptive Analysis Descriptive |
new molecular entities (NMEs)
|
||
| Intentional Self-Harm and Hospitalized Depression Following Sertraline Use: A Propensity Score Matched Analysis (A Follow-up to a Previous Analysis) Retrospective Inferential |
sertraline
|
hospitalized depression , intentional self-harm |
|
| Intentional Self-Harm and Hospitalized Depression Following Sertraline Use: A Propensity Score Matched Analysis Retrospective Inferential |
sertraline
|
hospitalized depression , intentional self-harm |
|
| Racial Differences in COVID-19 Outcomes (2020-2021) Retrospective Inferential |
Critical COVID-19 , death , hospitalization with COVID-19 |
||
| Use of Multiple Sclerosis Drugs Among Pregnant Women with Live-Birth Deliveries: A Descriptive Analysis Descriptive |
alemtuzumab, cladribine, dalfampridine, dimethyl fumarate, diroximel fumarate, fingolimod, glatiramer acetate, interferon beta-1A, interferon beta-1B, mitoxantrone, natalizumab, ocrelizumab, peginterferon beta-1a, siponimod, teriflunomide
|
||
| Oral Metoclopramide Use: A Descriptive Analysis Descriptive |
metoclopramide
|
||
| Utilization of Drugs with Approved Risk Evaluation and Mitigation Strategies (REMS) That Employ Elements to Assure Safe Use (ETASU) Summary Table |
drugs with REMS that employ ETASU
|
||
| Duration of Follow Up for New Molecular Entities Approved in 2017: First Descriptive Analysis Descriptive |
new molecular entities (NMEs)
|
||
| Brand and Generic Tacrolimus Use following Kidney, Heart, and Liver Transplants: A Descriptive Analysis Descriptive |
tacrolimus
|
||
| Incidence Rate of Severe Uterine Bleeding Among New Users of Oral Anticoagulants: A Descriptive Analysis Descriptive |
apixaban, dabigatran, oral anticoagulant, rivaroxaban, warfarin
|
severe uterine bleed |
|
| Utilization of Sacubitril/Valsartan: A Descriptive Analysis Descriptive |
sacubitril/valsartan
|
||
| Patterns in Insulin Product Use and Billing Codes: A Descriptive Analysis Descriptive |
insulin
|
||
| Duration of Follow Up for New Molecular Entities Approved in 2005, 2006, and 2007 Descriptive |
new molecular entities (NMEs)
|
||
| Duration of Follow Up for New Molecular Entities Approved in 2011 Descriptive |
new molecular entities (NMEs)
|
||
| Duration of Follow Up for New Molecular Entities Approved in 2008 and 2009 Descriptive |
new molecular entities (NMEs)
|
||
| Duration of Follow Up for New Molecular Entities Approved in 2010, 2012, and 2013 Descriptive |
new molecular entities (NMEs)
|
||
| Duration of Follow Up for New Molecular Entities Approved in 2014 and 2015 Descriptive |
new molecular entities (NMEs)
|
||
| Duration of Follow Up for New Molecular Entities Approved in 2016 Descriptive |
new molecular entities (NMEs)
|
||
| Follow-Up Time for Guselkumab, Risankizumab, and Tildrakizumab Users with Plaque Psoriasis: First Descriptive Analysis Descriptive |
guselkumab, risankizumab, tildrakizumab
|
||
| Angioedema following Dipeptidyl Peptidase IV (DPP IV) Inhibitors and Angiotensin Converting Enzyme (ACE) Inhibitors Use: A Descriptive Analysis Mini-Sentinel |
angiotensin-converting enzyme (ACE) inhibitor, dipeptidyl peptidase-IV (DPP-IV) inhibitor
|
angioedema |
|
| Venous and Arterial Thromboembolism among New Users of NuvaRing and Other Combined Hormonal Contraceptives: A Descriptive Analysis Descriptive |
combined hormonal contraceptives (CHCs), ethinyl estradiol (EE), NuvaRing
|
arterial thromboembolism (ATE) , venous thromboembolism (VTE) |
|
| Counts of Individuals in the Sentinel Distributed Database Descriptive |
|||
| Characterization of Mothers in the Mother-Infant Linkage Table in the Sentinel Distributed Database: A Descriptive Analysis Descriptive |
|||
| Pregnancy among Women with Heart Failure: A Descriptive Analysis Descriptive |
pregnancy |
||
| Serious Infections among Immunocompromised Health Plan Members Descriptive |
serious infection |
||
| Cutaneous Small-Vessel Vasculitis following Dabigatran, Rivaroxaban, and Apixaban Use in Patients with Atrial Fibrillation: A Propensity Score Matched Analysis Retrospective Inferential |
apixaban, dabigatran, direct oral anticoagulant (DOAC), rivaroxaban, warfarin
|
cutaneous small-vessel vasculitis |
|
| Direct Oral Anticoagulants (DOACs), Warfarin, Allopurinol, or Propylthiouracil Use in Patients with Cutaneous Small-Vessel Vasculitis: A Descriptive Analysis Descriptive |
allopurinol, direct oral anticoagulant (DOAC), propylthiouracil, warfarin
|
cutaneous small-vessel vasculitis |
|
| Prevalent and Incident Drug Use in a Pediatric Population: A Descriptive Analysis Mini-Sentinel |
acetaminophen with codeine, acyclovir, acyclovir sodium, albuterol, albuterol sulfate, levalbuterol HCL, levalbuterol tartrate, nitazoxanide, nizatidine, oxycodone HCL, sucralfate
|
||
| Abacavir, Carbamazepine, Clopidogrel, and Phenytoin Use: A Descriptive Analysis Mini-Sentinel |
abacavir, carbamazepine, clopidogrel, phenytoin
|
||
| Incidence of Acute Respiratory Failure (ARF) following Trimethoprim-Sulfamethoxazole (TMP-SMX) Use: A Descriptive Analysis Descriptive |
trimethoprim-sulfamethoxazole
|
acute respiratory failure |
|
| Thrombotic Events and Death in Inpatient-Identified COVID-19 Patients TriNetX Analysis |
thrombotic events |
||
| Thrombotic Events in COVID-19 Patients Not Requiring Hospitalization at the Time of Diagnosis TriNetX Analysis |
thrombotic events |
||
| Ustekinumab Dispensing Patterns: A Descriptive Analysis Descriptive |
adalimumab, certolizumab pegol, infliximab, ustekinumab, vedolizumab
|
||
| Risk of Cardiac Congenital Malformations Following Armodafinil or Modafinil Use: A Descriptive Analysis Descriptive |
armodafinil, modafinil
|
cardiac congenital malformations |
|
| Risk of Cardiac Congenital Malformations Following Armodafinil or Modafinil Use: A Propensity Score Matched Analysis Retrospective Inferential |
armodafinil, modafinil
|
cardiac congenital malformations |
|
| Counts of Individuals with Gout Using Urate-Lowering Therapy (ULT) and Switching between ULT Products: A Descriptive Analysis Descriptive |
allopurinol, febuxostat
|
||
| Incidence of Severe Uterine Bleed Following Novel Oral Anticoagulants Use: A Descriptive Analysis Descriptive |
apixaban, dabigatran, rivaroxaban, warfarin
|
severe uterine bleed |
|
| Mini-Sentinel: Diabetic Ketoacidosis following Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors, Sulfonylureas, Saxagliptin, and Sitagliptin Use: A Descriptive Analysis Descriptive |
saxagliptin, sitagliptin, sodium-glucose cotransporter-2 (SGLT-2) inhibitor, sulfonylurea
|
diabetic ketoacidosis |
|
| Thromboembolic Stroke, Intracranial Hemorrhage, Gastrointestinal Bleeding, and Major Extracranial Bleeding following Dabigatran, Rivaroxaban, and Apixaban Use in Patients Aged 64 and Younger with Atrial Fibrillation: A Propensity Score Matched Analysis Retrospective Inferential |
apixaban, dabigatran, non-vitamin K antagonist oral anticoagulants, rivaroxaban
|
gastrointestinal bleeding , intracranial hemorrhage , major extracranial bleeding , thromboembolic stroke |
|
| Wrong Frequency Errors with Low Dose Oral Methotrexate Descriptive |
methotrexate
|
||
| Acute Myocardial Infarction and Heart Failure following Saxagliptin or Sitagliptin Use: A Propensity Score Matched Analysis Retrospective Inferential |
long-acting insulin, pioglitazone, saxagliptin, second-generation sulfonylurea, sitagliptin
|
acute myocardial infarction (AMI) , heart failure |
|
| Factors Related to the Assignment of Sodium Glucose Cotransporter-2 Inhibitors (SGLT-2i) versus Dipeptidyl Peptidase-4 Inhibitors (DPP-4i) Retrospective Inferential |
sodium-glucose cotransporter-2 (SGLT-2) inhibitor
|
factors for treatment assignment |
|
| Frequency of Percutaneous Transluminal Septal Myocardial Ablation (PTSMA) and Estimated Incidence Rates of Post-PTSMA Cardiovascular Outcomes: A Descriptive Analysis Descriptive |
percutaneous transluminal septal myocardial ablation |
||
| Stroke, Intracranial Hemorrhage, and Bleeding following Dabigatran, Rivaroxaban, and Apixaban Use in Patients Aged 65 or Older: A Propensity Score Matched Analysis Retrospective Inferential |
apixaban, dabigatran, rivaroxaban
|
bleeding event , intracranial hemorrhage , stroke |
|
| Cutaneous Small-Vessel Vasculitis following Direct Oral Anticoagulants (DOACs), Warfarin, or Allopurinol Use in Patients with Atrial Fibrillation: A Descriptive Analysis Descriptive |
allopurinol, direct oral anticoagulant (DOAC), warfarin
|
cutaneous small-vessel vasculitis |
|
| Same Day Seizures following Gadolinium Based Contrast Agents: A Self-Controlled Risk Interval Analysis Custom Code |
gadolinium-based contrast agent (GBCA)
|
seizure |
|
| Ranitidine Drug Utilization Patterns Descriptive |
ranitidine
|
||
| Intravenous (IV) Iron Utilization Among Pregnant Women Descriptive |
intravenous (IV) iron
|
||
| Algorithms to Estimate Start of Pregnancy Using In-Vitro Fertilization (IVF), Intrauterine Insemination (IUI), and Select Prenatal Tests among Pregnancies Resulting in a Live-Born Delivery Descriptive |
|||
| Mini-Sentinel: Availability of International Normalized Ratio (INR) Laboratory Test Values and INR Test Procedures among New Warfarin Users Descriptive |
warfarin
|
||
| Spironolactone Use in Patients with Reduced Ejection Fraction Heart Failure (HFrEF) or Preserved Ejection Fraction Heart Failure (HFpEF) Descriptive |
spironolactone
|
||
| Sacubitril/Valsartan, Angiotensin-Converting Enzyme (ACE) Inhibitors, and Other Angiotensin II Receptor Blockers (ARBs) Use in Patients with Heart Failure Descriptive |
angiotensin II receptor blocker (ARB), angiotensin-converting enzyme (ACE) inhibitor, sacubitril/valsartan
|
||
| Mini-Sentinel: Switching Between Generic and Brand Clonazepam Mini-Sentinel |
clonazepam
|
||
| Glaucoma, Cataracts, Diminished Visual Acuity, and Nasal Septal Perforation following Mometasone Sinus Implant Use in Patients with Nasal Polyposis: A Descriptive Analysis Descriptive |
cataracts , diminished visual acuity , glaucoma , nasal septal perforation |
||
| Hypertension in Pediatric Patients: A Descriptive Analysis Descriptive |
hypertension |
||
| Use of Typical and Atypical Antipsychotics Among Infants Custom Code |
antipsychotic, atypical antipsychotic, typical antipsychotic
|
||
| Non-Melanoma Skin Cancer following Hydrochlorothiazide Use: A Propensity Score Matched Analysis Retrospective Inferential |
hydrochlorothiazide (HCTZ)
|
non-melanoma skin cancer |
|
| Total Enrollment with Medical and Drug Coverage Summary Table |
|||
| Trends in Penicillin Allergy Testing Descriptive |
penicillin allergy test
|
||
| Time Until Guillain-Barré Syndrome or Bell's Palsy Diagnosis following Initiation of Checkpoint Inhibitor Treatment Descriptive |
atezolizumab, avelumab, durvalumab, ipilimumab, nivolumab, pembrolizumab
|
Bell’s palsy , Guillain-Barré syndrome |
|
| Concurrent Use of Ticagrelor with Atorvastatin or Rosuvastatin Descriptive |
atorvastatin, rosuvastatin, ticagrelor
|
||
| Prenatal Tests in Women with Potential Stillbirths Descriptive |
prenatal tests
|
stillbirth |
|
| Duration of Follow-up for Individuals with Chronic Conditions Descriptive |
Alzheimer's disease , acquired hypothyroidism , acute myocardial infarction (AMI) , anemia , asthma , atrial fibrillation , benign prostatic hyperplasia , breast cancer , bronchiectasis , chronic conditions , chronic kidney disease (CKD) , chronic obstructive pulmonary disease , colorectal cancer , depression , diabetes , endometrial cancer , glaucoma , heart failure , hyperlipidemia , hypertension , ischemic heart disease , lung cancer , osteoarthritis , osteoporosis , prostate cancer , rheumatoid arthritis , stroke , transient ischemic attack (TIA) |
||
| Use of Metoclopramide among Patients with Diabetic Gastroparesis and Type 2 Diabetes Descriptive |
metoclopramide HCL
|
duration of use |
|
| Hydroxyurea Use in Patients with Sickle Cell Anemia Descriptive |
hydroxyurea
|
sickle cell anemia , use by indication |
|
| Mini-Sentinel: Summary of Antidiabetic Agent Use During Pregnancy Custom Code |
alpha-glucosidase inhibitor, amylin analog, biguanide, dipeptidyl peptidase-4 (DPP-4) inhibitor, glucagon-like peptide-1 (GLP-1) receptor agonists, injectable insulin, meglitinide analog, sulfonylurea, thiazolidinedione
|
exposure in pregnancy |
|
| Epidemiology of Pediatric Respiratory Syncytial Virus-Associated Illness in FDA’s Sentinel System Descriptive |
respiratory syncytial virus (RSV) , respiratory syncytial virus-associated illness |
||
| Estimating Optimal Quantities for Initial Opioid Analgesic Prescriptions for Acute Pain Conditions Presenting to Surgical Settings Custom Code |
opioid analgesic
|
drug refill probability |
|
| Respiratory Syncytial Virus in a Pediatric Population Descriptive |
respiratory syncytial virus (RSV) |
||
| Hydroxyprogesterone Caproate and Progesterone Use During Pregnancy Descriptive |
hydroxyprogesterone caproate, progesterone
|
exposure in pregnancy |
|
| Neuropsychiatric Events Following Montelukast Use: A Propensity Score Matched Analysis Retrospective Inferential |
montelukast
|
inpatient depressive disorder , outpatient depressive disorder , self-harm , suicide |
|
| Multiple Sclerosis Relapses among Copaxone, Glatopa, Gilenya, and Glatiramer Users Descriptive |
Copaxone, Gilenya, glatiramer, Glatopa
|
multiple sclerosis relapse |
|
| Cutaneous Small Vessel Vasculitis and Acute Kidney Injury Following Direct-Acting Oral Anticoagulant Use Descriptive |
direct oral anticoagulant (DOAC)
|
acute kidney injury , cutaneous small-vessel vasculitis |
|
| Non-Melanoma Skin Cancer following Hydrochlorothiazide Use Descriptive |
bendroflumethiazide (BFMTZ), chlorothiazide (CTZ), hydrochlorothiazide (HCTZ)
|
non-melanoma skin cancer |
|
| Sinus Stents with Mometasone and Diminished Visual Acuity Descriptive |
intranasal steroid, mometasone, oral steroid, sinus stent
|
blindness , cataract surgery , cataracts , diminished visual acuity , glaucoma |
|
| Use of Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin Receptor Blockers (ARB) in a Pediatric Population Descriptive |
angiotensin receptor blocker, angiotensin-converting enzyme (ACE) inhibitor
|
||
| Utilization Patterns of Qsymia (Phentermine/Topiramate) Descriptive |
phentermine HCl, phentermine/topiramate, Qsymia, topiramate
|
||
| Use of Higher Dosage Strength Oral and Transmucosal Opioid Analgesics Descriptive |
higher dosage strength opioid analgesic, lower dosage strength opioid analgesic, opioid analgesic, oral opioid analgesic, transdermal opioid analgesic, transmucosal opioid analgesic
|
||
| Ischemic Stroke, Intracranial Hemorrhage, and Gastrointestinal Hemorrhage Among New Users of Apixaban and Warfarin Descriptive |
apixaban, warfarin
|
gastrointestinal hemorrhage , intracranial hemorrhage , ischemic stroke |
|
| Use of Korlym and Mifeprex (Mifepristone) Descriptive |
Korlym, Mifeprex, mifepristone
|
||
| Antiemetic Use During Pregnancy Custom Code |
doxylamine, granisetron, metoclopramide HCL, netupitant/palonosetron HCl, ondansetron, palonosetron, prochlorperazine, promethazine HCl, succinate/pyridoxine HCl
|
exposure in pregnancy |
|
| Use of Valsartan, Angiotensin II Receptor Blockers (ARB), and Angiotensin-Converting Enzyme (ACE) Inhibitors Descriptive |
angiotensin II receptor blocker (ARB), angiotensin-converting enzyme (ACE) inhibitor, azilsartan medoxomil, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan
|
||
| New Users of Oral Bisphosphonates Mini-Sentinel |
bisphosphonate
|
||
| Neuropsychiatric Events following Montelukast Use Descriptive |
inhaled corticosteroid, montelukast, nasal corticosteroid, zafirlukast
|
neuropsychiatric event , psychotropic medication use , suicide |
|
| Duration of Use Among New Users of Hydrochlorothiazide (HCTZ), Angiotensin-Converting Enzyme Inhibitors (ACEIs), and Angiotensin II Receptor Blockers (ARBs) Descriptive |
angiotensin II receptor blocker (ARB), angiotensin-converting enzyme (ACE) inhibitor, hydrochlorothiazide (HCTZ)
|
||
| Severe Uterine Bleed Following Novel Oral Anticoagulants Use: A Propensity Score Analysis Retrospective Inferential |
apixaban, dabigatran, novel oral anticoagulant (NOAC), rivaroxaban, warfarin
|
severe uterine bleed |
|
| Leuprolide Acetate Use Among Patients with Central Precocious Puberty Descriptive |
leuprolide acetate
|
central precocious puberty |
|
| Gadolinium-Based Contrast Agents (GBCAs) Use in Pregnancy Descriptive |
gadolinium-based contrast agent (GBCA)
|
exposure in pregnancy |
|
| Duration of Follow-Up and Treatment for Non-Insulin Antidiabetic Drugs Descriptive |
non-insulin antidiabetics
|
||
| Dolutegravir Use During Pregnancy Descriptive |
dolutegravir
|
exposure in pregnancy |
|
| Acute Myocardial Infarction and Stroke Among Patients with Testosterone-Related Indications Mini-Sentinel |
testosterone
|
acute myocardial infarction (AMI) , stroke |
|
| Brintellix and Brilinta Medication Errors due to Name Confusion Descriptive |
Brilinta, Brintellix
|
medication error |
|
| Characteristics of Gout Patients and Use of Urate-Lowering Therapies Descriptive |
urate-lowering therapies
|
||
| SGLT-2 Inhibitor Use and Incidence of Diabetic Ketoacidosis in Patients with Type 1 Diabetes Mellitus Descriptive |
canagliflozin, dapagliflozin, empagliflozin, sitagliptin, sodium-glucose cotransporter-2 (SGLT-2) inhibitor
|
diabetic ketoacidosis |
|
| Stroke, Gastrointestinal Bleeding, and Intracranial Hemorrhage Following Apixaban or Warfarin Use in Patients with Non-Valvular Atrial Fibrillation: A Propensity Score Matched Analysis Retrospective Inferential |
apixaban
|
gastrointestinal (GI) bleed , intracranial hemorrhage , stroke |
|
| Optimal Initial Length of Opioid Prescription Descriptive |
opioid analgesic
|
||
| Seizure Following Ranolazine Use Retrospective Inferential |
Ranexa, ranolazine
|
seizure |
|
| Use of Multiple Sclerosis Drugs Among Pregnant Women Descriptive |
alemtuzumab, daclizumab, dalfampridine, dimethyl fumarate, fingolimod, glatiramer acetate, interferon beta-1A, interferon beta-1A/albumin, interferon beta-1B, mitoxantrone, natalizumab, peginterferon beta-1a, teriflunomide
|
pregnancy |
|
| Pulmonary Arterial Hypertension and Interstitial Lung Disease Events Among Interleukin Inhibitor Users Descriptive |
interleukin-1/-6 inhibitor
|
interstitial lung disease , pulmonary arterial hypertension |
|
| Duration of Use for Teriparatide Descriptive |
teriparatide
|
||
| Quantifying Prevalence and Mortality Associated with Neonatal Enteroviral Sepsis (NES) Using Inpatient Data in FDA’s Sentinel System Custom Code |
neonatal enteroviral sepsis (NES) |
||
| COPD, Asthma, and Respiratory Disease Effectiveness (CARE) For 21st Century Cures: Feasibility Assessments for Comparative Effectiveness Studies Custom Code |
asthma , chronic obstructive pulmonary disease |
||
| Counts and Proportions of New Users of Fentanyl Transdermal System with Evidence of Prior Opioid Tolerance Mini-Sentinel |
fentanyl transdermal system
|
||
| Phosphodiesterase Type 5 (PDE-5) Inhibitor Utilization Among Women Descriptive |
phosphodiesterase type 5 (PDE5) inhibitor
|
||
| Sofosbuvir and Amiodarone Use and Bradycardia or Pacemaker Insertion Descriptive |
amiodarone, sofosbuvir
|
bradycardia , pacemaker insertion |
|
| Algorithms Evaluating Dabigatran Use and Acute Myocardial Infarction Compared with Warfarin Retrospective Inferential |
dabigatran, warfarin
|
acute myocardial infarction (AMI) |
|
| Use of Dabigatran and Intracranial Hemorrhage, Gastrointestinal Hemorrhage, Ischemic Stroke, and Acute Myocardial Infarction Retrospective Inferential |
dabigatran
|
acute myocardial infarction (AMI) , gastrointestinal hemorrhage , intracranial hemorrhage , ischemic stroke |
|
| New Pediatric Users of Leuprolide Acetate Descriptive |
leuprolide acetate
|
||
| Prevalence and Incidence of Progressive Multifocal Leukoencephalopathy (PML), Clostridium Difficile, and Cytomegalovirus (CMV) Diagnoses Mini-Sentinel |
clostridium difficile , cytomegalovirus (CMV) , progressive multifocal leukoencephalopathy (PML) |
||
| Incident Use of Selective Serotonin Reuptake Inhibitor Antidepressants Mini-Sentinel |
selective serotonin reuptake inhibitor (SSRI)
|
||
| Identifying Suicide Codes in the Sentinel Distributed Database (SDD) Custom Code |
suicide |
||
| Clostridium difficile Infection Following Use of Vancomycin, Fidaxomicin, or Metronidzaole Mini-Sentinel |
fidaxomicin, metronidazole, vancomycin
|
clostridium difficile |
|
| Availability of International Normalized Ratio (INR) Laboratory Test Values and Test Procedures Among Warfarin Users Mini-Sentinel |
warfarin
|
||
| Warfarin Use Followed by International Normalized Ratio (INR) Lab Codes Mini-Sentinel |
warfarin
|
||
| Top Ten Causes of Death Descriptive |
|||
| Prevalent and Incident Use of Fingolimod Mini-Sentinel |
fingolimod
|
||
| Risk of Acute Myocardial Infarction and Stroke among Carbidopa/Levodopa, Entacapone, and Carbidopa/Levodopa/Entacapone Users Mini-Sentinel |
carbidopa/levodopa, carbidopa/levodopa/entacapone (Stalevo), entacapone
|
||
| Prevalence and Incident Use of Promethazine Mini-Sentinel |
promethazine, promethazine/codeine, promethazine/phenylephrine/codeine
|
||
| Use of Clonazepam Mini-Sentinel |
clonazepam
|
||
| Diagnosis of Agranulocytosis Following New Use of Anti-epileptic Drugs, Clozapine, and Olanzapine Mini-Sentinel |
carbamazepine, clozapine, lamotrigine, levetiracetam, ofatumumab, olanzapine, topiramate
|
agranulocytosis |
|
| Counts and Prevalence of Alendronate, Risedronate, Ibandronate, and Zolendronate Summary Table |
alendronate sodium, alendronate sodium/vitamin d3, bandronate sodium, calcitonin salmon, calcitonin, salmon, synthetic, denosumab, ibandronate sodium, raloxifene HCL, risedronate sodium, risedronate sodium/calcium carbonate, teriparatide, zoledronic acid, zoledronic acid reclast, zoledronic acid/mannitol and water, zoledroniccid reclast, zoledroniccid zometa
|
||
| Counts and Prevalence of Linezolid and Vancomycin Summary Table |
linezolid, vancomycin
|
||
| Use of Atrial Fibrillation Drugs Summary Table |
dofetilide, sotalol HCL
|
||
| Incident Use of Hepatitis C Virus (HCV) Drugs Summary Table |
boceprevir, ledipasivir/sofosbuvir, simeprevir sodium, sofosbuvir, telaprevir
|
||
| Concomitancy and Indications for Idelalisib Use Descriptive |
bendamustine, bortezomib, chlorambucil, cyclophosphamide, doxorubicin, ibritumomab, ibrutinib, idelalisib, lenalidomide, obinutuzumab, ofatumumab, prednisone, rituximab, vincristine
|
||
| Prevalent and Incident Use of Generic Name Kinase Inhibitors Summary Table |
afatinib dimaleate, axitinib, bortezomib, cabozantinib s-malate, carfilzomib, ceritinib, crizotinib, dabrafenib mesylate, dasatinib, erlotinib HCL, everolimus, gefitinib, ibrutinib, idelalisib, imatinib mesylate, lapatinib ditosylate, nilotinib HCL, pazopanib HCL, ponatinib HCL, regorafenib, ruxolitinib phosphate, sorafenib tosylate, sunitinib malate, trametinib dimethyl sulfoxide, vandetanib, vemurafenib
|
||
| Incident Use of Rivaroxaban Mini-Sentinel |
rivaroxaban
|
||
| Selected Medications and Death, with Linkage of Mini-Sentinel Distributed Database with NDI+ Mini-Sentinel |
amiodarone, amitriptyline, amoxapine, amoxicillin, amoxicillin with clavulanate, azithromycin, cephalexin, ciprofloxacin, citalopram, clarithromycin, clindamycin, clomipramine, desipramine, desvenlafaxine, dofetilide, doxepin, dronedarone, duloxetine, erythromycin, escitalopram, flecainide, fluoxetine, fluvoxamine, gemifloxacin, imipramine, levofloxacin, levomilnacipran, maprotiline, mirtazapine, moxifloxacin, nefazodone, norfloxacin, nortriptyline, ofloxacin, paroxetine, penicillin V, propafenone, protriptyline, sertraline, sotalol, telithromycin, trazodone, trimethoprim-sulfamethoxazole, trimipramine, venlafaxine, vilazodone, vortioxetine
|
sudden cardiac death |
|
| Venous Thromboembolism Following Continuous or Extended Cycle Contraceptive Use: A Propensity Score Matched Analysis Retrospective Inferential |
combined oral contraceptive (COC)
|
venous thromboembolism (VTE) |
|
| Combined Oral Contraceptives Containing Ethinyl Estradiol and Levonorgestrel and Venous Thromboembolism Descriptive |
combined oral contraceptive (COC)
|
venous thromboembolism (VTE) |
|
| Exposure to Intravenous (IV) Iron Procedures and Anaphylaxis and Epinephrine Events Mini-Sentinel |
intravenous (IV) iron
|
anaphylaxis , epinephrine event |
|
| Counts, Prevalence, and Incidence of Intravenous (IV) Iron Products Summary Table |
ferumoxytol, iron dextran complex, iron sucrose complex, sodium ferric gluconate complex
|
||
| Rhabdomyolysis and/or Creatine Kinase Laboratory Results Following New Use of Statins or Angiotensin-Converting Enzyme Inhibitors Descriptive |
angiotensin-converting enzyme (ACE) inhibitor, statin
|
creatine kinase laboratory result , rhabdomyolysis |
|
| Use of Tyrosine Kinase Inhibitors (TKIs) Descriptive |
axitinib, pazopanib, sorafenib, sunitinib, tyrosine kinase inhibitor
|
||
| Length of Follow-up Time for New Users of Immunosuppressive Drugs Retrospective Inferential |
adalimumab, alemtuzumab, certolizumab, dalfampridine, dimethyl fumarate, etanercept, fingolimod, glatiramer acetate, golimumab, infliximab, interferon beta-1A, interferon beta-1B, mitoxantrone, natalizumab, pegylated interferon beta-1A, teriflunomide, ustekinumab
|
||
| Prevalent and Incident Dispensings of Ranolazine Summary Table |
ranolazine
|
||
| Boceprevir, Ledipasivir/Sofosbuvir, Simeprevir Sodium, Sofosbuvir, and Telaprevir Use Summary Table |
boceprevir, ledipasivir/sofosbuvir, simeprevir sodium, sofosbuvir, telaprevir
|
hepatitis C |
|
| Prevalent and Incident Use of SGLT2 Inhibitors Descriptive |
canagliflozin, canagliflozin/metformin HCl, dapagliflozin propanediol, dapagliflozin/metformin HCl, empagliflozin, empagliflozin/linagliptin
|
||
| Concomitant Use of Opioid Analgesics and Cytochrome P450 (CYP) Inhibitors and Inducers Summary Table |
CYP inducer, CYP inhibitor, oxycodone, oxymorphone
|
||
| Metabolic Effects of Second Generation Antipsychotics in Youth, Subprojects 1, 2, and 3 Custom Code |
aripiprazole, olanzapine, quetiapine, risperidone, second generation antipsychotic (SGA)
|
metabolic syndrome , type 2 diabetes mellitus , weight gain |
|
| Antiepileptic Drug (AED) Injection Procedure Codes Retrospective Inferential |
anti-epileptic drug (AED)
|
||
| PROMPT: Rivaroxaban Surveillance Summary Table |
rivaroxaban, warfarin
|
gastrointestinal (GI) bleed , intracranial hemorrhage , ischemic stroke |
|
| Counts of Commonly Used Angiostensin-Converting Enzyme (ACE) Inhibitors and Beta Blockers Summary Table |
angiotensin-converting enzyme (ACE) inhibitor, beta blocker
|
||
| Drug and Medical Enrollment Counts Summary Table |
|||
| A Protocol for Assessment of Dabigatran and Selected Safety Outcomes Retrospective Inferential |
dabigatran, warfarin
|
intracranial hemorrhage , ischemic stroke , major extracranial hemorrhage |
|
| Use of Tumor Necrosis Factor (TNF) Blocker Drugs Summary Table |
tumor necrosis factor (TNF) blocker
|
||
| Characterization of Pediatric Medical Conditions: Respiratory Syncytial Virus (RSV) Associated Illness Descriptive |
respiratory syncytial virus (RSV) |
||
| Molecularly Targeted Anti-Cancer Therapies Summary Table |
axitinib, bicalutamide, crizoatinib, dasatinib, erlotinib HCL, everolimus, gefitinib, imatinib mesylate, lapatinib ditosylate, nilotinib HCL, pazopanib HCL, ruxolitinib phosphate, sorafenib tosylate, sunitinib malate, tamoxifen citrate, vandetanib, vemurafenib, vismodegib
|
||
| Stroke Diagnosis Codes Summary Table |
stroke |
||
| Length of Enrollment in Pediatric Population Descriptive |
|||
| Prevalent and Incident Use of Isotretinoin Summary Table |
isotretinoin
|
||
| Occurrence of Selected Generic Drugs 13 Summary Table |
amlodipine besylate, efalizumab, ibandronate sodium, lamotrigine, leflunomide, maraviroc, metoclopramide HCL, nitrofurantoin, nitrofurantoin macrocrystal, nitrofurantoin monohyd/m-crystal, propylthiouracil, quinine, quinine sulfate, ramipril, rosiglitazone maleate, sibutramine HCL m-hydrate, tadalafil, varenicline tartrate
|
||
| Clostridium Difficile Prevalence and Vancomycin, Fidaxomicin, and Tocilizumab Use Summary Table |
fidaxomicin, tocilizumab, vancomycin
|
clostridium difficile |
|
| Use of Dronedarone HCL Summary Table |
dronedarone HCL
|
||
| Incident and Prevalent Dispensings of Mirabegron Summary Table |
mirabegron
|
||
| Use of Ospemifene, Boceprevir, and Telaprevir Summary Table |
boceprevir, ospemifene, telaprevir
|
||
| Prevalent and Incident Use of Testosterone Products Summary Table |
testosterone
|
||
| Top 100 Procedures and Diagnoses 30 Days Surrounding Incident Warfarin Use Mini-Sentinel |
warfarin
|
||
| Anti-Tumor Necrosis Factor (TNF) Utilization Among Pregnant Women Descriptive |
adalimumab, certolizumab, etanercept, golimumab, infliximab, tumor necrosis factor (TNF) alpha inhibitor
|
||
| Prevalent and Incident Use of Romiplostim Summary Table |
romiplostim
|
||
| Suicide Diagnoses Summary Table |
suicide |
||
| Incident and Prevalent Use of Generic Drugs for Overactive Bladder Summary Table |
darifenacin hydrobromide, fesoterodine fumarate, oxybutynin chloride, solifenacin succinate, tolterodine tartrate, trospium chloride
|
||
| Use of Cancer Drugs Summary Table |
crizoatinib, erlotinib HCL, ipilimumab, nivolumab, pembrolizumab
|
||
| Antipsychotic Use and Dementia Diagnoses Summary Table |
antipsychotic
|
dementia |
|
| Genetic Testing Procedures Summary Table |
|||
| Atrial Fibrillation Prevalence Summary Table |
atrial fibrillation , atrial flutter |
||
| Mycophenolate Dispensings and Procedures Summary Table |
mycophenolate mofetil, mycophenolate mofetil HCL, mycophenolate sodium
|
||
| Mycophenolate Dispensings and Procedures (by Quarter) Summary Table |
mycophenolate mofetil, mycophenolate mofetil HCL, mycophenolate sodium
|
||
| Niacin and Fenofibrate Use and Outcomes with Propensity Score Matching Mini-Sentinel |
extended-release (ER) niacin, fenofibrate
|
gastrointestinal (GI) bleed , intracranial hemorrhage , ischemic stroke |
|
| Stroke Following Typical or Atypical Antipsychotic Use in Non-Elderly Patients: A Propensity Score Matched Analysis Retrospective Inferential |
antipsychotic
|
stroke |
|
| Stroke Following Atypical Antipsychotic or Z-Hypnotic Use in Patients with Prior Use of Selective Serotonin Reuptake Inhibitors (SSRIs): A Propensity Score Matched Analysis Retrospective Inferential |
aripiprazole, fluoxetine, olanzapine, quetiapine, risperidone
|
stroke |
|
| Antipsychotics and Stroke Descriptive |
aripiprazole, atypical antipsychotic, haloperidol, olanzapine, olanzapine/fluoxetine, quetiapine, risperidone, selective serotonin reuptake inhibitor (SSRI), typical antipsychotic
|
intracranial hemorrhage , ischemic stroke |
|
| Sodium/Glucose Cotransporter (SGLT2) Inhibitors- Type 1 and Type 2 Diabetes Cohort Identification Descriptive |
dipeptidyl peptidase-4 (DPP-4) inhibitor, sodium-glucose cotransporter-2 (SGLT-2) inhibitor, sulfonylurea
|
diabetes , type 1 diabetes mellitus , type 2 diabetes mellitus |
|
| Niacin and Niacin Combination Products, Fenofibrates, and Omega-3 Products Summary Table |
fenofibrate, niacin, niacin/lovastatin, niacin/simvastatin, omega-3 product
|
||
| Alosetron Use Summary Table |
alosetron HCL
|
||
| Mirabegron Use Summary Table |
mirabegron
|
||
| Pegylated Products Use Summary Table |
certolizumab pegol, methoxy peg-epoetin beta, pegademase bovine, peginterferon beta-1a, pegloticase, pegvisomant
|
||
| Pegylated Products Follow-Up Request Summary Table |
|||
| New Molecular Entities Approved in 2010-2015 Summary Table |
abiraterone acetate, aclidinium bromide, ado-trastuzumab emtansine, afatinib dimaleate, albiglutide, alcaftadine, alectinib HCL, alglucosidase alfa, alirocumab, alogliptin benzoate, apixaban, apremilast, aripiprazole, aripiprazole lauroxil, asfotase alfa, asparaginase, avanafil, axitinib, azilsartan medoxomil, bazedoxifene, bedaquiline fumarate, belatacept, belimumab, belinostat, blinatumomab, boceprevir, bosutinib, brexpiprazole, cabazitaxel, cabozantinib, canagliflozin, cangrelor tetrasodium, carfilzomib, carglumic acid, cariprazine HCL, ceftaroline fosamil acetate, ceftazidime/avibactam, ceftolozane, ceritinib, cholic acid, clobazam, cobicistat, cobimetinib fumarate, collagenase clostridium histolyticum, crofelemer, dabigatran etexilate mesylate, dabrafenib mesylate, daclatasvir dihydrochloride, dalbavancin HCL, dalfampridine, dapagliflozin propanediol, daratumumab, deferiprone, denosumab, deoxycholic acid, dimethyl fumarate, dinutuximab, dolutegravir sodium, droxidopa, dulaglutide, edoxaban tosylate, efinaconazole, eliglustat tartrate, elosulfase alfa, elotuzumab, eluxadoline, elvitegravir, elvitegravir/cobicistat/emtricitabine/tenofovir, empagliflozin, enzalutamide, eribulin mesylate, eslicarbazepine acetate, estradiol valerate/dienogest, estrogen, evolocumab, ezogabine, fidaxomicin, fingolimod HCL, flibanserin, florbetapir f-18, fluconazole, flutemetamol f-18, gabapentin enacarbil, gadobutrol, gadoterate meglumine, glucarpidase, ibrutinib, icatibant acetate, idarucizumab, idelalisib, incobotulinumtoxina, indacterol maleate, ingenol mebutate, insulin degludec, ioflupane i-123, ipilimumab, isavuconazonium sulfate, ivabradine HCL, ivacaftor, ixazomib citrate, ledipasvir, lenvatinib mesylate, linaclotide, linagliptin, liraglutide, lomitapide mesylate, lorcaserin HCl, lucinactant, luliconazole, lumacaftor/ivacaftor, lurasidone HCL, macitentan, mepolizumab, metreleptin, miltefosine, mipomersen sodium, naloxegol oxalate, necitumumab, netupitant, nintedanib esylate, nivolumab, obinutuzumab, ocriplasmin, olaparib, olodaterol HCL, omacetaxine mepesuccinate, ombitasvir, oritavancin diphosphate, osimertinib mesylate, ospemifene, palbociclib, palonosetron HCL, panobinostat lactate, parathyroid hormone, paritaprevir, pasireotide diaspartate, patiromer calcium sorbitex, peginterferon beta-1a, pegloticase, pembrolizumab, peramivir, pirfenidone, pitavastatin, polidocanol, pomalidomide, radium-223 dichloride, ramucirumab, rilpivirine HCL, riociguat, rivaroxaban, roflumilast, rolapitant HCL, ruxolitinib phosphate, sacubitril/valsartan, sebelipase alfa, secukinumab, selexipag, siltuximab, simeprevir sodium, sofosbuvir, sonidegib phosphate, spinosad, sugammadex sodium, sulfur hexafluoride microsphere, suvorexant, tasimelteon, tazobactam, tedizolid phosphate, teduglutide, telaprevir, tenofovir disoproxil fumarate, teriflunomide, tesamorelin acetate, ticagrelor, tocilizumab, tofacitinib citrate, trabectedin, trametinib dimethyl sulfoxide, trifluridine/tipiracil HCL, ulipristal acetate, umeclidinium, uridine, vandetanib, vedolizumab, velaglucerase alfa, vemurafenib, vilanterol, vilazodone HCL, vismodegib, vorapaxar sulfate, vortioxetine hydrobromide, ziv-aflibercept
|
||
| Indications of Use Among Oral Antifungal Drug Users Descriptive |
fluconazole, griseofulvin, itraconazole, ketoconazole, terbinafine
|
||
| Actemra (Tocilizumab) Utilization Among Pregnant Women Descriptive |
Actemra, tocilizumab
|
juvenile rheumatoid arthritis , rheumatoid arthritis |
|
| Anti-epileptic Drugs and Angioedema Descriptive |
lacosamide, lamotrigine, levetiracetam, oxcarbazepine, phenytoin
|
angioedema |
|
| Drug Use Following Genetic Testing Among Patients with Cancer Descriptive |
afatinib dimaleate, BCR-ABL, bosutinib, BRAF, BRCA, cetuximab, cobimetinib fumarate, dabrafenib mesylate, dasatinib, erlotinib HCL, estimated glomerular filtration rate (eGFR), gefitinib, imatinib mesylate, KRAS, nilotinib HCL, olaparib, osimertinib mesylate, panitumumab, ponatinib HCL, trametinib dimethyl sulfoxide, vemurafenib
|
cancer |
|
| Multiple Births and Preterm Deliveries Descriptive |
preterm delivery |
||
| Influenza Antiviral Drug Use 2010-2015 Descriptive |
oseltamivir, zanamivir
|
||
| Prevalent Dispensings of Ticagrelor (Brilinta) and Vortioxetine Hydrobromide (Brintellix) Summary Table |
Brilinta, Brintellix, ticagrelor, vortioxetine hydrobromide
|
||
| Attention Deficit Hyperactivity Disorder (ADHD) Medications and Heart Failure Descriptive |
amphetamine, methylphenidate, Strattera
|
heart failure or cardiomyopathy |
|
| PROMPT: Mirabegron Surveillance Prospective Sequential Inferential |
mirabegron, oxybutynin
|
acute myocardial infarction (AMI) , stroke |
|
| Dronedarone and Electrocardiograms Descriptive |
dronedarone
|
electrocardiogram |
|
| Parenteral Iron and Anaphylactoid Reactions Custom Code |
parenteral iron (IV iron)
|
anaphylactoid reaction |
|
| Dabigatran and Warfarin Use Among Members with Atrial Fibrillation and Other Pre-Existing Conditions Descriptive |
dabigatran, warfarin
|
||
| MRI and GBCA Procedures Descriptive |
|||
| Hysterectomy Procedures Among Females Descriptive |
hysterectomy , morcellation , uterine fibroid |
||
| Most Frequent Generic Dispensings Among Members Aged 65+ Descriptive |
|||
| Incident Testosterone Indication Diagnoses and Testosterone Use Mini-Sentinel |
testosterone
|
||
| Hypogonadism and Testosterone Use Mini-Sentinel |
testosterone
|
hypogonadism |
|
| Incident Testosterone Use Mini-Sentinel |
testosterone
|
||
| Immunoglobulin Products and Hemolysis Mini-Sentinel |
immunoglobulin (Ig)
|
hemolysis |
|
| New Use of Statins and Rhabdomyolysis Mini-Sentinel |
atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, statin
|
rhabdomyolysis |
|
| Epidural Steroid Use Mini-Sentinel |
epidural steroid
|
||
| Serum Creatinine Procedures and Labs Mini-Sentinel |
|||
| Isotretinoin and Long-term Antibiotic Use and Multiple Sclerosis Mini-Sentinel |
abacavir, doxycycline, erythromycin, isotretinoin, lamivudine, long-term antibiotic, minocycline, zidovudine
|
multiple sclerosis |
|
| Omalizumab or Montelukast Use Among Individuals with Asthma and Acute Myocardial Infarction, Stroke, Intracranial Hemorrhage, or Pulmonary Embolism Mini-Sentinel |
omalizumab
|
acute myocardial infarction (AMI) , intracranial hemorrhage , stroke |
|
| Laparoscopic Hysterectomy With and Without Robotic Assistance and Adverse Outcomes Mini-Sentinel |
laparoscopic hysterectomy
|
intraoperative complication , medical complication , surgical site complication |
|
| New Use of Dabigatran or Warfarin and Gastrointestinal Hemorrhage or Intracerebral Hemorrhage Events Mini-Sentinel |
dabigatran, warfarin
|
gastrointestinal hemorrhage , intracerebral hemorrhage (ICH) |
|
| New Use of Anti-Epileptic Drugs and Agranulocytosis Mini-Sentinel |
anti-epileptic drug (AED), carbamazepine, lamotrigine, levetiracetam, topiramate
|
absolute neutrophil count (ANC) , agranulocytosis |
|
| IVIg Product Use and Hemolysis Events Mini-Sentinel |
flebogamma, Gammagard, Gammaplex, Gamunex, intravenous immunoglobulin (IVIg), Octagam, Privigen
|
||
| Incident Use of Testosterone Products Among All Members and Members with Pre-Existing Testosterone Use Mini-Sentinel |
Androgel, Axiron, Fortesta, intramuscular testosterone, methyltestosterone, Striant, Testim, testosterone, testosterone cypionate, testosterone enanthate, testosterone pellet, testosterone propionate, testosterone suspension, transdermal testosterone
|
||
| Concomitant Use of Niacin and Statins and Concomitant Use of Fenofibrates and Statins Mini-Sentinel |
fenofibrate, niacin, statin
|
||
| Anticoagulant Use Among Members with Atrial Fibrillation and Various Pre-Existing Exlusions Mini-Sentinel |
anticoagulant, dabigatran, warfarin
|
||
| Anticoagulant Use Among Members with Pre-Existing Atrial Fibrillation and Various Pre-Existing Exclusions Mini-Sentinel |
anticoagulant, dabigatran, warfarin
|
||
| Antidepressant Use and Bleeding Events Mini-Sentinel |
antidepressant, selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), tricyclic
|
bleeding event , gastrointestinal hemorrhage , intracerebral hemorrhage (ICH) |
|
| Dabigatran Uptake and Persistence Mini-Sentinel |
dabigatran
|
||
| Incident Antipsychotic Use Mini-Sentinel |
antipsychotic, aripiprazole, asenapine, clozapine, iloperidone, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone
|
||
| Indications of Intravenous Immunoglobulin Use Mini-Sentinel |
intravenous immunoglobulin (IVIg)
|
||
| Anticoagulants and Bleeding Events Mini-Sentinel |
anticoagulant, dabigatran, warfarin
|
bleeding event |
|
| Anticoagulant Use Among Patients with Atrial Fibrillation Descriptive |
anticoagulant, dabigatran, oral formulation of apixaban, rivaroxaban, warfarin
|
||
| Drug Use Among Pregnant Women with Live Births Mini-Sentinel |
angiotensin-converting enzyme (ACE) inhibitor, anticonvulsant, dabigatran, lisinopril, methotrexate, mycophenolate mofetil, paroxetine, ribavirin, selective serotonin reuptake inhibitor (SSRI), simvastatin, sodium valproate, statin, valproic acid, warfarin
|
||
| Anti-Diabetes Drugs and Acute Myocardial Infarction, Hospitalized Heart Failure Mini-Sentinel |
anti-diabetic agent (ADA), dipeptidyl peptidase-4 (DPP-4) inhibitor, glimepiride, glipizide, glyburide, hypoglycemic drug, long-acting insulin, pioglitazone, saxagliptin, sitagliptin, sulfonylurea, thiazolidinedione
|
acute myocardial infarction (AMI) , heart failure |
|
| Select Bisphosphonates and Select Outcomes of Interest Mini-Sentinel |
biphosphonate
|
esophageal cancer , fractures , hip fracture , non-vertebral fracture , osteonecrosis of the jaw |
|
| Anaphylaxis Events Following Incident Vaccine Exposure Among Members with a Pre-Existing Condition of Milk Allergy Mini-Sentinel |
diphtheria, tetanus, acellular pertussis (DTaP) vaccine, diphtheria, tetanus, acellular pertussis (DTaP)-haemophilus influenzae type B (HIB) vaccine, diphtheria, tetanus, acellular pertussis (DTaP)-haemophilus influenzae type B (HIB)-inactivated polio vaccine (IPV), diphtheria, tetanus, acellular pertussis (DTaP)-hepatitis B (Hep B)-inactivated polio vaccine (IPV), diphtheria, tetanus, acellular pertussis (DTaP)-inactivated polio vaccine (IPV), tetanus, diphtheria, pertussis (Tdap) vaccine
|
anaphylactic shock |
|
| Gastrointestinal Disorders Mini-Sentinel |
entercolitis , gastrointestinal disorder , ileocolitis , procitis , proctosigmoiditis , pseudopolyposis , regional enteritis , ulcerative colitis |
||
| Injection Omalizumab Procedure Codes Mini-Sentinel |
omalizumab
|
||
| Omalizumab Use Mini-Sentinel |
omalizumab
|
||
| Prevalent and Incident Use of Pramipexole Mini-Sentinel |
pramipexole
|
||
| Hypoglycemic Events Following Use of Anti-Diabetic Agents (ADAs) Mini-Sentinel |
anti-diabetic agent (ADA), chlorpropamide, glimepiride, glipizide, glipizide/metformin, glyburide, glyburide/metformin, insulin, metformin, pioglitazone, pioglitazone/metformin, rosiglitazone maleate, rosiglitazone/metformin, tolazamide
|
hypoglycemia |
|
| Omalizumab and Montelukast Use Mini-Sentinel |
montelukast, omalizumab
|
||
| Progressive Multifocal Leukoencephalapathy Mini-Sentinel |
progressive multifocal leukoencephalopathy (PML) |
||
| Methotrexate and Tofacitinib Use Mini-Sentinel |
methotrexate, methotrexate sodium, methotrexate sodium, preservative free, tofacitinib citrate
|
||
| Incident and Prevalent Use of Alvimopan, Naltrexone, and Methylnaltrexone Mini-Sentinel |
alvimopan, methylnaltrexone bromide, morphine sulfate/naltrexone, naltrexone, naltrexone HCL, naltrexone microsphere
|
||
| Procedure Codes Related to Memory Gel Breast Implants Mini-Sentinel |
breast implant
|
||
| Opioid Medication Use Mini-Sentinel |
Buprenex, Butrans, generic injectable buprenorphine, generic oral buprenorphine, generic powder buprenorphine, opioid, Suboxone, Subutex
|
||
| Buprenorphine Product Use Mini-Sentinel |
buprenorphine
|
||
| CPAX Aneurysm Procedure Codes Mini-Sentinel |
CPAX aneurysm , emboli detection , intravenous microbubble injection , surgery of intracranial aneurysm , transcranial doppler study |
||
| Lap-band Diagnosis Codes Mini-Sentinel |
gastric lap band
|
bariatric surgery , gastric band procedure |
|
| Activa Tremor Control Procedures Mini-Sentinel |
Activa Tremor Control |
||
| Ascension Metacarpophalangeal Diagnoses Mini-Sentinel |
Ascension metacarpophalangeal (MCP) , arthritis , diffuse disease of connective tissue , osteoarthritis , sprain and strain of metacarpophalangeal of hand , traumatic arthropathy |
||
| Ascension Metacarpophalangeal Procedures Mini-Sentinel |
arthroplasty metacarpophalangeal interphalangeal joint , arthrotomy for removal of prosthesis , division of joint |
||
| CPAX Aneurysm Diagnoses Mini-Sentinel |
CPAX aneurysm , aneurysm , arthropod-borne hemorrhagic fever , cerebral aneurysm nonruptured , intracerebral hemorrhage (ICH) , mosquito-borne viral encephalitis , subarcahnoid hemorrhage |
||
| Activa Tremor Control Diagnoses Mini-Sentinel |
neuropacemaker
|
Activa Tremor Control , essential tremor , other specified forms of tremor , paralysis agitans |
|
| Dialysis HCPCS Procedure Codes Mini-Sentinel |
dialysis , end-stage renal disease (ESRD) , kidney failure |
||
| Dialysis ICD9 Diagnosis Codes Mini-Sentinel |
dialysis , end-stage renal disease (ESRD) , kidney failure |
||
| Dialysis ICD9 Procedure Codes Mini-Sentinel |
dialysis , end-stage renal disease (ESRD) , kidney failure |
||
| Antiepileptic Drugs (AEDs) and Kidney Stones 2 Mini-Sentinel |
anti-epileptic drug (AED), carbamazepine, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, phenytoin, topiramate, valproic acid, zonisamide
|
kidney stone |
|
| Infectious Disease Diagnoses Mini-Sentinel |
Chagas disease , anthrax , ascariasis , hepatitis , hepatitis C , hookworm , influenza , leishmaniasis , malaria , methicillin-resistant Staphylococcus aureus (MRSA) , plague , schistosomiasis , trichuriasis , tuberculosis (TB) , tularemia |
||
| Anti-Infective Agents Use 2 Mini-Sentinel |
anti-infective agent
|
||
| Cardiovascular Therapy Agent Use 2 Mini-Sentinel |
acebutolol HCL, cardiovascular therapy agent
|
||
| Gastrointestinal Therapy Agents Use 2 Mini-Sentinel |
gastrointestinal therapy agent
|
||
| Occurrence of Selected Generic Drugs 12 Summary Table |
|||
| Analgesic Use 3 Summary Table |
analgesic
|
||
| Diabetes Diagnoses and Occurrence of Laboratory Results Mini-Sentinel |
|||
| Anti-D, Dexamethasone, Prednisone, Romiplostim and Hemolysis Mini-Sentinel |
anti-D, dexamethasone, prednisone, romiplostim
|
hemolysis |
|
| Immune Globulin Use Summary Table |
immune globulin, gamma (IgG), immune globulin, gamma (IgG)/maltose, immune globulin, gamma caprylate (IgG)
|
||
| Injection Gammagard Use Summary Table |
Gammagard
|
||
| Hemorrhagic Disorder Diagnoses Summary Table |
acquired hemophilia , hemorrhagic disorder |
||
| Occurrence of Kidney Stones Mini-Sentinel |
anti-diabetic agent (ADA)
|
kidney stone |
|
| Enoxaparin Sodium Use Summary Table |
enoxaparin sodium
|
||
| Injection Enoxaparin Sodium Use Summary Table |
enoxaparin sodium
|
||
| Hemodialysis Procedures Summary Table |
hemodialysis |
||
| Occurrence of Selected Dental HCPCS Codes Summary Table |
|||
| Acute Kidney Failure Diagnoses Summary Table |
acute kidney failure |
||
| Nursing Home Facility HCPCS Codes Summary Table |
|||
| Prevalent and Incident Use of Acetazolamide Summary Table |
acetazolamide
|
||
| Long Acting Beta2-Agonists (LABA) Policies and Drug Utilization Patterns Mini-Sentinel |
long-acting beta2 agonist (LABA)
|
change in drug utilization patterns |
|
| Prevalent and Incident Use of Quinine Sulfate Mini-Sentinel |
quinine sulfate
|
||
| Quinine Sulfate, Diltiazem and Selected Thrombotic Events Mini-Sentinel |
diltiazem, quinine sulfate
|
hemolytic-uremic syndrome , immune thrombocytopenic purpura , other secondary thrombocytopenia , thrombotic microangiopathy , unspecified thrombocytopenia |
|
| Anti-Seizure Medication Use Mini-Sentinel |
carbamazepine, ethosuxamide, felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, phentermine HCl, phentermine resin, phenytoin, phenytoin sodium, phenytoin sodium extended, pregabalin, tiagabine HCL, topiramate, valproic acid, zonisamide
|
||
| Occurrence of Selected Generic Drugs 11 Mini-Sentinel |
benzyl alcohol, boceprevir, dabigatran etexilate mesylate, eltrombopag olamine, febuxostat, pitavastatin calcium, Pradaxa, rivaroxaban, telaprevir, vigabatrin
|
||
| Multiple Sclerosis Medication Use Mini-Sentinel |
fingolimod HCL, glatiramer acetate, interferon beta-1A, interferon beta-1A/albumin, interferon beta-1B, mitoxantrone HCL, natalizumab
|
||
| Multiple Sclerosis Medication Injections Mini-Sentinel |
injection glatiramer acetate, injection interferon beta-1A, injection interferon beta-1A, injection interferon beta-1B, injection mitoxantrone HCL, injection natalizumab
|
||
| Antiepileptic Drugs (AEDs) and Kidney Stones Mini-Sentinel |
anti-epileptic drug (AED), carbamazepine, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, phenytoin, topiramate, zonisamide
|
kidney stone |
|
| Chronic Kidney Disease Diagnoses Mini-Sentinel |
chronic kidney disease (CKD) |
||
| Nursing Home HCPCS Codes Mini-Sentinel |
|||
| Occurrence of Selected Generic Drugs 10 Mini-Sentinel |
allopurinol, diclofenac, isoniazid, lapatinib, telithromycin, ticlopidine
|
||
| Antiepileptic Drug Use Mini-Sentinel |
acetazolamide, carbamazepine, clobazam, clonazepam, diazepam, ethosuxamide, ezogabine, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam, lorazepam, oxcarbazepine, phenobarbital, phenytoin, pregabalin, primidone, rufinamide, tiagabine, topiramate, valproic acid, vigabatrin, zonisamide
|
||
| Oral Antifungal Use Mini-Sentinel |
fluconazole, itraconazole, ketoconazole, posaconazole, terbinafine, voriconazole
|
||
| Propylthiouracil and Methimazole Use 2 Mini-Sentinel |
methimazole, propylthiouracil
|
||
| Unspecified Anterior Pituitary Hyperfunction and Hypertrophy of the Breast Diagnoses Mini-Sentinel |
anterior pituitary hyperfunction , hypertrophy |
||
| HIV and HBV Infection Diagnoses Mini-Sentinel |
hepatitis B virus (HBV) , human immunodeficiency virus (HIV) |
||
| Bupropion HCL Sustained Release HCPCS Codes Mini-Sentinel |
bupropion HCL sustained release tablet
|
||
| Occurrence of Selected Generic Drugs 9 Mini-Sentinel |
ezetimibe/simvastatin, lisinopril, lisinopril/dietary sup. Cmb10, lisinopril/hydrochlorothiazide, methotrexate, methotrexate sodium, mycophenolate mofetil, mycophenolate sodium, niacin/simvastatin, paroxetine HCL, paroxetine mesylate, ribavirin, ribavirin/interferon alfa-2B, simvastatin, valproic acid, warfarin sodium
|
||
| Analgesic Use 2 Mini-Sentinel |
acetaminophen with codeine, aspirin/codeine phosphate, codeine phosphate, codeine sulfate, fentanyl citrate, methadone HCL, morphine sulfate, oxycodone HCL, oxymorphone HCL, sulindac, tramadol HCL
|
||
| Anti-Infective Agents Use Mini-Sentinel |
acyclovir, acyclovir sodium, atovaquone, doxycycline calcium, doxycycline hyclate, nitazoxanide, norfloxacin, telithromycin, tenofovir disoproxil fumarate
|
||
| Cardiovascular Therapy Agents Use Mini-Sentinel |
acebutolol HCL, aliskiren hemifumarate, ambrisentan, amlodipine besylate, atenolol, betaxolol HCL, bosentan, captopril, carvedilol, conivaptan HCL, diltiazem HCL, eprosartan mesylate, indapamide, labetalol HCL, lisinopril, metoprolol succinate, metoprolol tartrate, metoprolol/hydrochlorothiazide, nadolol, nimodipine, perindopril erbumine, propafenone HCL, trandolapril, triamterene
|
||
| Gastrointestinal Therapy Agents Use Mini-Sentinel |
aprepitant, cimetidine, dexlansoprazole, dicyclomine HCL, fosaprepitant dimeglumine, lubiprostone, mesalamine, nizatidine, sucralfate
|
||
| Occurrence of Selected Generic Drugs 8 Mini-Sentinel |
alosetron HCL, alvimopan, ambrisentan, bosentan, buprenorphine HCL, bupropion HCL, isotretinoin, lenalidomide, metoclopramide HCL, naloxone HCL, nilotinib HCL, propoxyphene HCL, propoxyphene HCL/acetaminophen, propoxyphene HCL/ASA/caffeine, ribavirin/interferon alfa-2B, rosiglitazone/glimepiride, rosiglitazone/metformin HCL, sacrosidase, sibutramine HCL, thalidomide, varenicline tartrate
|
||
| Occurrence of Selected Generic Drugs 7 Mini-Sentinel |
albuterol, albuterol sulfate, alvimopan, calcium acetate, chlorambucil, cyclosporine, cyclosporine modified, levalbuterol HCL, levalbuterol tartrate, lindane, phytonadione, solifenacin succinate, tretinoin, vorinostat
|
||
| Oxicam NSAIDs, Modafinil/Armodafinil, Sulfamothoxazole and Severe Cutaneous Adverse Reaction (SCAR) Events Mini-Sentinel |
modafinil, modafinil/armodafinil, oxicam, sulfamothoxazole
|
severe cutaneous adverse reaction (SCAR) |
|
| Angiotensin Receptor Blockers (ARBs), Hydrochlorothiazide, Atenolol, Amlodipine Use and Celiac Disease Mini-Sentinel |
amlodipine, angiotensin II receptor blocker (ARB), atenolol, candesartan, eprosartan, hydrochlorothiazide (HCTZ), irbesartan, losartan, olmesartan, telmisartan, valsartan
|
celiac disease |
|
| Parkinson’s Disease Medication Use Mini-Sentinel |
carbidopa, combination product of carbidopa, entacapone, levodopa, levodopa and entacapone (Stalevo)
|
||
| Occurrence of Selected Pediatric Drugs 1 Mini-Sentinel |
acetaminophen with codeine, acyclovir, albuterol, nizatidine, sucralfate
|
||
| Vascular Endothelial Growth Factor (VEGF) Inhibitor Prevalent and Incident Use Mini-Sentinel |
bevacizumab, sorafenib, sunitinib, thalidomide, vascular endothelial growth factor (VEGF) inhibitor
|
||
| Dabigatran, Rivaroxaban, and Warfarin Use Mini-Sentinel |
dabigatran, rivaroxaban, warfarin
|
||
| Dabigatran, Warfarin and GI Bleed, Intracerebral Hemorrhage Mini-Sentinel |
dabigatran, warfarin
|
gastrointestinal hemorrhage , intracerebral hemorrhage (ICH) , serious bleeding |
|
| Warfarin and GI Bleed, Intracerebral Hemorrhage Mini-Sentinel |
warfarin
|
gastrointestinal hemorrhage , intracerebral hemorrhage (ICH) , serious bleeding |
|
| Dabigatran (Pradaxa), Warfarin and Gastrointestinal Bleed, Intracerebral Hemorrhage Mini-Sentinel |
anticoagulant, blood thinner, Coumadin, dabigatran, Pradaxa, warfarin
|
gastrointestinal hemorrhage , intracerebral hemorrhage (ICH) , serious bleeding |
|
| Lindane Use Modular Program Mini-Sentinel |
lindane
|
||
| Natalizumab, Efalizumab, and Progressive Multifocal Leukoencephalopathy (PML) Mini-Sentinel |
efalizumab, natalizumab
|
progressive multifocal leukoencephalopathy (PML) |
|
| Selgiline Use Mini-Sentinel |
selgiline
|
||
| Bupropion and Naltrexone Use 2 Mini-Sentinel |
bupropion, naltrexone
|
||
| Bupropion and Naltrexone Use 1 Mini-Sentinel |
bupropion, naltrexone
|
||
| Duloxetine, Pregabalin, and Milnacipran Use 1 Mini-Sentinel |
duloxetine, milnacipran, pregabalin
|
||
| Duloxetine, Pregabalin, and Milnacipran Use 2 Mini-Sentinel |
duloxetine, milnacipran, pregabalin
|
||
| Clopidogrel and Prasugrel Use Mini-Sentinel |
clopidogrel, prasugrel
|
||
| Occurrence of Selected Generic Drugs 6 Mini-Sentinel |
abacavir sulfate, didanosine, didanosine/calcium carb/mag, didanosine/sodium citrate, efavirenz/emtricitab/tenofovir, emtricitabine, emtricitabine/tenofovir, entecavir, lamivudine, stavudine, tenofovir disoproxil fumarate, zidovudine
|
||
| Nucleoside Reverse Transcriptase Inhibitor Procedures Mini-Sentinel |
didanosine, injection zidovudine, zidovudine oral
|
||
| Amphotericin Use Mini-Sentinel |
amphotericin B, amphotericin B cholesteryl sulfate, amphotericin B lipid complex, amphotericin B liposome
|
||
| Isoniazid Use Mini-Sentinel |
isoniazid, rifampin/isoniazid, rifampin/isoniazid/pyrazinamid
|
||
| Boceprevir and Telaprevir Use Mini-Sentinel |
boceprevir, telaprevir
|
||
| Injection Amphotericin Procedures Mini-Sentinel |
injection amphotericin B, injection amphotericin B cholesteryl, injection amphotericin B lipid complex, injection amphotericin B lipid form, injection amphotericin B liposome
|
||
| Hip Implant Procedures and Diagnoses 2 Mini-Sentinel |
acetabular component , acquired hemophilia , femoral component , mechanical complication of internal orthopedic device implant and graft , partial hip replacement , total hip replacement |
||
| Occurrence of Selected Generic Drugs 4 Mini-Sentinel |
meloxicam, modafinil, piroxicam, sulfamethoxazole, trimethoprim-sulfamethoxazole
|
||
| Golimumab, Ustekinumab, and Dronedarone Hydrochloride Use (by Quarter) Mini-Sentinel |
dronedarone HCL, golimumab, ustekinumab
|
||
| Occurrence of Selected Generic Drugs 5 Mini-Sentinel |
alosetron HCL, ambrisentan, bosentan, buprenorphine HCL, eltrombopag olamine, fentanyl, hydromorphone HCL, isotretinoin, lenalidomide, mifepristone, oxycodone HCL, romiplostim, rosiglitazone maleate, rosiglitazone/glimepiride, rosiglitazone/metformin HCL, thalidomide, vigabatrin
|
||
| Natalizumab and Efalizumab Use Mini-Sentinel |
efalizumab, natalizumab
|
||
| Occurrence of Selected Generic Drugs 3 Mini-Sentinel |
alosetron HCL, ambrisentan, bosentan, buprenorphine HCL, fentanyl, hydromorphone HCL, isotretinoin, lenalidomide, methadone HCL, morphine sulfate, naloxone HCL, oxycodone HCL, rosiglitazone maleate, rosiglitazone/glimepiride, rosiglitazone/metformin HCL, thalidomide
|
||
| Golimumab, Ustekinumab, and Dronedarone Hydrochloride Use (by Year) Mini-Sentinel |
dronedarone HCL, golimumab, ustekinumab
|
||
| Injection Ustekinumab and Injection Denosumab Procedures Mini-Sentinel |
injection ustekinumab
|
||
| Injection Natalizumab Procedures Mini-Sentinel |
injection natalizumab
|
||
| Drugs that Act on the Renin-Angiotensin-Aldosterone System (Angiotensin Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, Aliskiren) and Angioedema Mini-Sentinel |
aliskiren, angiotensin II receptor blocker (ARB), angiotensin-converting enzyme (ACE) inhibitor
|
angioedema |
|
| Occurrence of Selected Generic Drugs 1 Mini-Sentinel |
azathioprine, azathioprine sodium, benzonatate, cabergoline, everolimus, lopinavir/ritonavir, mercaptopurine, ralegravir potassium, ribavirin, ribavirin A-2B, tenofovir disoproxil fumarate, tolvaptan, voriconazole
|
||
| Occurrence of Selected HCPCS Codes 1 Mini-Sentinel |
cabergoline oral, combination peginterferon and ribavirin, mercaptopurine oral, negative pressure wound therapy (NPWT)
|
||
| Occurrence of Selected HCPCS Codes 2 Mini-Sentinel |
busulfan, chlorambucil, cyclophosphamide, finasteride, methotrexate, trastuzumab
|
||
| Infliximab Use Mini-Sentinel |
infliximab
|
||
| Injection Infliximab Procedures Mini-Sentinel |
injection infliximab
|
||
| Analgesics Use Mini-Sentinel |
analgesic
|
||
| Dalfampridine Use Mini-Sentinel |
dalfampridine
|
||
| Propylthiouracil and Methimazole Use Mini-Sentinel |
methimazole, propylthiouracil
|
||
| Occurrence of Selected Generic Drugs 2 Mini-Sentinel |
acitretin, acitretin/emollient combo. 26, ambrisentan, bosentan, busulfan, chlorambucil, clarithromycin, cyclophosphamide, dronedarone, finasteride, fluconazole, isotretinoin, lenalidomide, lisinopril, lisinopril/hydrochlorothiazide, lithium carbonate, lithium citrate, methimazole, methotrexate, methotrexate sodium, telavancin, thalidomide, topiramate, trastuzumab, valproic acid, warfarin
|
||
| Lindane Use Summary Table Summary Table |
lindane
|
||
| Regional Enteritis and Ulcerative Enterocolitis Diagnoses Mini-Sentinel |
Crohn's disease , regional enteritis , ulcerative enterocolitis |
||
| Arthritis Diagnoses Mini-Sentinel |
Felty's syndrome , arthritis , inflammatory polyarthropathy , juvenile chronic polyarthritis , rheumatoid arthritis |
||
| Clozapine Use Mini-Sentinel |
clozapine
|
||
| Use of Vascular Endothelial Growth Factor (VEGF) Inhibitors Mini-Sentinel |
bevacizumab, sorafenib tosylate, sunitinib malate, thalidomide, vascular endothelial growth factor (VEGF) inhibitor
|
||
| Bone Resorption Inhibitor Use (by Drug Class) Mini-Sentinel |
bone resorption inhibitor
|
||
| VEGF and Bone Resorption Inhibitor Procedures Mini-Sentinel |
bone resorption inhibitor procedure , vascular endothelial growth factor (VEGF) |
||
| Negative Pressure Wound Therapy (NPWT) Procedures Mini-Sentinel |
negative pressure wound therapy (NPWT) |
||
| Hip Implant Procedures and Diagnoses Mini-Sentinel |
arthroplasty , hemiarthroplasty , hip implant , hip replacement |
||
| Milk Allergy Diagnoses Mini-Sentinel |
milk allergy |
||
| Progressive Multifocal Leukoencephalopathy Diagnoses Mini-Sentinel |
progressive multifocal leukoencephalopathy (PML) |
||
| Hyperlipidemia Diagnoses Mini-Sentinel |
hypercholesterolemia , hyperchylomicronemia , hyperglyceridemia , hyperlipidemia |
||
| Heart/Lung Resuscitation (CPR), Injection Diphenhydramine Hydrochloride (HCL), Injection Adrenaline Epinephrine Procedures Mini-Sentinel |
injection adrenaline epinephrine, injection diphenhydramine hydrochloride (HCL)
|
cardiopulmonary resuscitation (CPR) |
|
| Unspecified Allergic Reaction Diagnoses Mini-Sentinel |
unspecified allergic reaction |
||
| Cardiopulmonary Resuscitation (CPR) Not Otherwise Specified Procedures Mini-Sentinel |
cardiopulmonary resuscitation (CPR) |
||
| Asthma Diagnoses Mini-Sentinel |
asthma |
||
| Acute Myocardial Infarction Diagnoses Mini-Sentinel |
acute myocardial infarction (AMI) |
||
| Serious Cutaneous Adverse Reaction (SCAR) Diagnoses Mini-Sentinel |
severe cutaneous adverse reaction (SCAR) |
||
| Aseptic Necrosis of Bone Jaw Diagnoses Mini-Sentinel |
aseptic necrosis of bone jaw |
||
| Angiotensin II Receptor Blockers and Celiac Disease Mini-Sentinel |
angiotensin II receptor blocker (ARB), candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan
|
celiac disease |
|
| Smoking Cessation Drugs and Cardiovascular Outcomes Mini-Sentinel |
bupropion, varenicline
|
acute coronary occlusion without myocardial infarction , acute myocardial infarction (AMI) , cardiovascular outcome , intermediate coronary syndrome , unstable angina |